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Cardiovascular disease, mainly due to atherosclerotic degeneration of the
arterial vasculature, continues to be the prominent cause of death and
disablement in the modern Western world. In particular large and medium-
sized elastic and muscular arteries are involved, leading to ischemia of the
heart, brain, or extremities1. To preserve blood flow, the saphenous vein was
first successfully employed to bypass a peripheral arterial obstruction by Kunlin
in 19482. Also in coronary heart disease, the introduction of bypass grafting3
was prosperous and has lead to dramatic increases in life expectancy. Even
percutaneous transluminal angioplasty (PTA)4, a minimal invasive, relatively
easy and fast technique has never been able to challenge bypass graft
supremacy. Up till now, bypass surgery has proven to confer superior patency
rates in the treatment of coronary as well as peripheral arterial obstructive
disease5-7. However, also in bypass grafting the problem of stenosis and
subsequent bypass failure exists. To maximize patency, different conduits and
surgical techniques have been considered. In coronary bypass surgery for
instance, alternatives have been found in arterial conduits like the internal
thoracic artery, and radial artery. Though favored by superior long-term
outcome, difficulties in obtaining the artery and an increased risk of spasm
hamper efficacy of this option. Moreover, due to fragility and small size, arterial
conduits are not feasible as peripheral bypass grafts. Other alternatives like
prosthetic grafts from polytetrafluoroethylene (PTFE) or Dacron have been used
when autologous veins were considered unsuitable due to degenerative
disease. However, concluding evidence shows a clear difference in patency,
favoring non-diseased autogenous conduits5. 
Pathology of vein graft disease
The course of venous graft disease can be subdivided into three more or 
less distinct sequential processes: thrombosis, intimal hyperplasia, and
atherosclerosis (Figure 1). 
Thrombosis
Graft thrombosis is a major complication in the first month after surgery8,9.
Early graft failure, as a rule within one week of operation, is mostly due to
surgical imperfection, inaccurate inflow of the graft or poor runoff as a result of
occlusive disease elsewhere in the arterial tract. Other negative aspects emerge
later after implantation of the autologous vein, when alterations in the vessel
wall, altered flow dynamics, and changes in blood rheology cause thrombosis
9
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(Virchow’s triad). First, surgical manipulation of the venous conduit might lead
to endothelial disruption, which in turn relates to a procoagulent condition of
the graft by fibrin accumulation on the luminal surface, and adherence 
of platelets and neutrophils10. This process is aggravated by the altered
hemodynamic milieu, i.e., high pulsatile pressure and increased flow.
Consequently, endothelial and smooth muscle cells express (or fail to express)
genes that govern the production of molecules and surface receptors that affect
vessel thrombogenicity. Thrombomodulin, a membrane-bound anti-thrombotic
regulatory protein, modulates the activity of thrombin from that of a
procoagulent to an anticoagulant protease11. When bound to thrombomodulin,
thrombin is unable to generate fibrin or activate platelets but instead leads to
activation of the circulating anticoagulant molecule, protein C. Undesirably,
harvesting of the vein as well as arterial perfusion of the vein graft have negative
effects on thrombomodulin activity12, 13. Furthermore, intrinsic differences
between arteries and veins make the antithrombotic properties of veins less
pronounced, indicated by decreased nitric oxide (NO) and prostacyclin
production capacity. Finally, the hampered vein is more susceptible to
circulating vasoconstricting agents (e.g. endothelin-1), which might lead to
decreased flow, increased risk of stasis, and consequent graft failure10.
Intimal hyperplasia 
Early in embryological development the establishment of blood flow and
increase of blood pressure instigate distinct differences between veins and
arteries. Vasculogenesis refers to the process of blood vessel development from
mesoderm-derived angioblasts, which differentiate into endothelial cells (EC)
and form a tubular network. This primitive vascular system then later is
extended by the budding of preexisting vessels (angiogenesis). Subsequently,
recruitment and incorporation of primordial vascular smooth muscle cells (SMC)
11
Figure 1. 
Different stages of vein graft disease. A. Hemodynamic forces (shear stress, tangential strain) alter
the vascular endothelium, which triggers a cascade of events, like recruitment of leukocytes and
platelets. B. Aggregation of platelets on the surface of the vessel wall induces thrombus formation
which hampers vein graft survival. C. Cytokines and growth factors are released by inflammatory
cells, generating a mitogenic milieu. SMCs migrate, proliferate and synthesize extracellular matrix
components. D. Late atherosclerosis. Accumulation of macrophages, T-lymphocytes, and foam
cells in a fibrocalcific lesion. Inflammatory mediators and proteases induce thinning of the fibrous
cap, rendering the plaque weak and susceptible to rupture and thrombus formation. Modified
from Dzau et al, 2002.
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around the endothelial tubes takes place to form the definitive vascular
structures. Again, hemodynamic forces seem to govern this progress into
arteries, arterioles, venules, and veins14.    
The human vein consists of three layers. The normal intima is thin,
overlying an often incomplete internal elastic lamina. The media is more
heterogeneous than that of arteries of similar size, consisting of a mixture of
mostly circularly arranged SMCs, extracellular matrix proteins and some elastic
fibers with no distinct external elastic lamina. The adventitia is composed of
abundant amounts of collagen with a lesser amount of elastic fibers.
Generally, veins implanted in the arterial circulation attempt to adapt to
the changed environment, and all of afore mentioned three venous layers undergo
significant changes during adjustment to the arterial circumstances. Briefly,
venous neointima formation is the most prominent adjustment which is
characterized by medial SMC proliferation and migration to the intima, further
proliferation in the intima and matrix deposition by these SMCs. The first step in
this process is endothelial denudation caused by vein handling during surgery
and hemodynamic stress once in circulation15. The areas where there is a lack
of endothelium get covered by platelets, over which a new endothelial cell layer
can be formed. These platelets secrete growth factors (PDGF, TGFb), which
promote SMC migration and proliferation10. The still present, but often
damaged endothelium usually is activated and releases growth factors and
cytokines which in turn activate SMCs (see further). Further thickening of the
tunica media and neointima is caused by invading perivascular fibroblasts,
which acquire alpha-smooth muscle actin and differentiate into myofibroblasts.
Migration of SMCs and fibroblasts is facilitated by matrix degeneration, more
specifically basement membrane degradation. Matrix metalloproteinases (MMP)
are capable of matrix and basement membrane degradation and are
upregulated in vein graft disease16,17,18. In addition, neutrophil and
monocyte/macrophage recruitment and progress into the vascular wall is
augmented by local upregulation of adhesion molecules. This leucocyte
invasion further adds to the ongoing inflammatory process and neointima
formation induced by cytokine secretion.  
Atherosclerosis 
After surviving the risk of early (thrombosis) and mid-early (intima hyperplasia)
failure, beyond the first year after surgery the dominant process underlying the
attrition of vein grafts is atherosclerosis. In principle, the fundamental process
of atheroma development is not different from which occurs in arteries.
However, vein graft atherosclerosis differs in the rapidly progressive nature of
12
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atheroma formation. Moreover, histological and morphological differences
have been described whereas vein graft atherosclerotic lesions exhibit more
inflammatory cells and are more diffuse, concentric, and vulnerable. These
differences might be explained by inferior compensatory mechanisms in veins.
For example, veins show higher levels of oxidative stress and inferior lipid
handling19. Furthermore, more extensive endothelial cell injury and
dysfunction is suggested to cause accelerated atherosclerosis20. 
Role of endothelium in venous remodeling   
Physiologically, the endothelial cell layer provides a non-permeable barrier
protecting underlying SMCs from humoral factors, inflammatory mediators, and
physical forces. It also produces a number of basement membrane components
to further exclude harmful stimuli. Furthermore, the intact endothelium
modulates vascular tone and local hemostasis, and maintains SMC quiescence
by production of regulating agents such as nitric oxide (NO) and prostacyclin
(PGI2)21,22. Injury of the endothelium upsets the balance between
vasoconstriction and vasodilatation and initiates a number of processes that
induce unfavorable remodeling23.
Hemodynamics 
Endothelial cells have the capacity to sense fluctuations in physical forces
caused by alterations in blood flow. Variations in blood flow are translated into
fluid shear stress and mechanical cyclic strain, which both have been
implicated in endothelial dysfunction and vascular remodeling24,25. Long-term
increase in blood flow is seen in surgical vein grafts implanted in the arterial
circulation. Consequently, the vessel answers by structural remodeling, such
that the diameter is reshaped to restore shear stress and cyclic strain to its
baseline levels. The early remodeling response is shear stress mediated and
involves predominantly NO and PGI2, highly potent vasodilators which cause a
sudden increase in lumen diameter. Detailed expositions of the biology of 
flow-induced vasodilatation can be found elsewhere26. Briefly, eNOS, a
constitutively expressed endothelial enzyme, is activated by intracellular [Ca++]
increase following acute shear stress elevation and in turn catalyzes NO
production. Released NO reduces Ca++ influx in SMCs and blocks the
phosphorylation of troponin, thereby inhibiting the activation of the 
Ca++-dependent myosin light chain kinase, effectuating SMC relaxation and
vasodilatation or ‘outward remodeling’27,28. NO, in addition to a key regulator
13
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of vascular tone, also possesses strong anti-inflammatory, anti-apoptotic, anti-
mitogenic, and anti-thrombotic properties29(Figure 2). 
However, NO bioavailability is markedly reduced in vein grafts within 1
day after implantation in de arterial circulation, and NO-mediated
endothelium-dependent relaxation is lost30. Mechanisms underlying alterations
in NO bioavailability are varied and multifactorial. Nevertheless, NO
bioactivity is strongly reduced by reactive oxygen species (ROS), more
specifically superoxide (O2
-). Superoxide is one of the most important ROS in
the vasculature, and is markedly increased in saphenous vein grafts, while ROS
scavengers are downregulated19. Superoxide degrades NO thus generating
other ROS like peroxynitrite (ONOO-)31(Figure 1). Loss of NO and increase in
oxidative stress leads to activation of nuclear factor-kappa β (NF)-ΚB, a
transcription factor which is a profound indicator of (endothelial) cell
activation. NF-ΚB is also activated by altered hemodynamic flow, inflammatory
mediators, growth factors and other cardiovascular risk factors32,33.
14
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Figure 2. 
Illustration showing the beneficial effects of nitric oxide (NO). NO exerts its protective effects by
inducing SMC relaxation; inhibiting SMC proliferation, migration, and extracellular matrix
synthesis; inhibiting platelet and leukocyte adhesion and activation; and protecting endothelial
integrity. Modified from Dzau et al, 2002.
Furthermore, the active form of NF-ΚB is present at different locations of
cardiovascular disease, and is responsible for the expression of several
proinflammatory genes, including shear force related genes33. Thus, NF-ΚB
might play an integral role in gene regulatory responses to flow34,35. Many of
these gene products have modulating effects on neointima formation, by direct
stimulation of SMC migration and proliferation, or by facilitating and boosting
the inflammatory response. PDGF, bFGF, TGF-β and endothelin-1 are up-
regulated in endothelium due to increased shear stress, and directly induce
SMC activation/proliferation via a paracrine mechanism36,37,38. Interleukin (IL)-
1β39, IL-840, and vascular endothelial growth factor (VEGF)38 are also up-
regulated by disturbed flow but have pro-inflammatory effects. Inflammatory
mechanisms have been implicated in neointima formation, particularly via the
afore mentioned NF-ΚB pathway41. Upon activation several pro-inflammatory
cytokines are released, which in turn stimulate recruited leukocytes to secrete
growth factors and proteases, further aggravating inflammation and neointima
formation. Initially, these immune cells (e.g. monocyte derived macrophages
and T-lymphocytes) are drawn towards the injured vascular wall by chemotactic
factors, one of which is the very potent monocyte chemotactic protein-1 (MCP-1).
MCP-1 is secreted by various cells like SMCs42, fibroblasts43, and shear stressed
ECs44, and is associated with development of intimal hyperplasia in vein
grafts45. Recruitment of inflammatory cells out of the blood stream into the
vascular wall is facilitated by adhesion molecules expressed on ECs46. Initial
adhesion of leukocytes to the endothelium is mediated by adhesion molecules
E- and P-selectin, which establish a relatively low strength interaction47,48.
More stable adhesion involves vascular cell adhesion molecule-1 (VCAM-1),
intercellular adhesion molecule-1 (ICAM-1), and platelet cell adhesion
molecule-1 (PECAM-1), which are responsible for transmigration into the
subendothelial area of leukocytes that secrete growth factors promoting
neointima formation49,50,51. In culured ECs, increased shear stress up-regulates
ICAM-1 and P-selectin, while E-selectin is unaffected, and VCAM-1 even 
seems to be down-regulated52,53,54. However, a study of adhesion molecule
expression in saphenous vein segments revealed up-regulation of ICAM-1, P-
selectin, but also VCAM-1 after distention pressure55. Up-regulation of
adhesion molecules facilitates leukocyte binding and migration through the
endothelial cell layer and the underlying tunica media. An additional strategy
for enhanced cell migration is degradation of extracellular matrix (ECM)
components by matrix metallo-proteinases (MMP). Two members of the MMP
family, proteolytic enzymes MMP-2 and MMP-9, have recently been implicated
in venous remodeling after bypass grafting17. Their activity is tightly regulated
15
General introduction
by tissue inhibitors of metalloproteinases (TIMP)56, but in activated form they
can digest several ECM and basement membrane components, suggesting to be
a prerequirement for most, if not all, cellular migration processes. Interestingly,
MMP-2 and MMP-9 have been found up-regulated in different vascular cells by
several culprits of vein graft disease57,58,59(see further). In addition to earlier
mentioned contributors to venous neointima formation, also the expression and
activity of MMP-2 and MMP-9 are increased in saphenous vein endothelium by
‘arterial’ shear stress and in saphenous vein grafts by mechanical stretching and
surgical preparative injury60,61,16,62. 
Relatively new in the pathogenesis of vein graft disease are some members
of the heat shock protein (HSP) family. HSPs are constitutionally expressed in
virtual all eukaryotic cell types and show high homologous sequences between
different species (molecular mimicry), from bacteria to humans63. To protect
their integrity, cells produce high levels of HSP in response to several stress
stimuli like heat shock, mechanical stress, infection, oxidants, and cytokine
exposure64,65,66. Recently, autogenous HSPs emerged as potential targets of the
innate immune system, thus being linked to several autoimmune-related
diseases. The introduction of HSPs in the pathogenesis of cardiovascular
diseases is of even more recent history. In fact, it was only in 1990 when
Berberian et al. for the first time found HSP expression in atherosclerotic
plaques, which not much later was followed by Wick et al. who showed a clear
relationship between HSP65 and induction of atherosclerotic lesions,
suggesting involvement of an autoimmune response to HSPs67,68. ECs respond
to unfavorable flow circumstances by a marked increase in HSP production,
which attracts immune cells to the endothelium and induces an autoimmune
response. In harmony, it was found that serum levels of antibodies against
human HSP60 are markedly correlated to cardiovascular disease69. Moreover,
human HSP60 was found to induce E-selectin, ICAM-1, and VCAM-1
expression on ECs, mentioned above as important molecules in adhesion and
migration of inflammatory cells70. The pro-inflammatory potential of HSP60
was stretched even further by the observation that HSP60 induced IL-6
production by vascular SMCs and activated monocytes/macrophages, thus
promoting the innate immune response71. All together, this suggests that
unfavorable flow dynamics trigger the endothelium to cause and facilitate a
generalized inflammatory response, that in turn adds to the process of growth
factor induced neointima formation.
Infection, inflammation and the endothelium
The endothelium is the first line of defense in protecting the vascular wall
16
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against the harmful potential of blood elements. It has been well understood
that systemic inflammation and other cardiovascular risk factors can
compromise endothelial function, giving rise to atherosclerotic deformation of
the vascular wall23. Reports on the effect of circulating risk factors and systemic
inflammation in the pathogenesis of venous intimal thickening are rare, but
since endothelial dysfunction is tightly associated with vein graft disease, this
risk pattern might very well apply to venous neointima formation as well. First,
experimental inflammation impairs endothelium-dependent vasodilatation and
antithrombotic properties of the vascular endothelium in arteries and veins, thus
increasing the risk of vasospasm, thrombosis and consequent graft failure after
venous bypass surgery72. Furthermore, acute inflammation results in a boost of
circulating cytokines, like IL-1, IL-6, IL-8, and TNF-α, and several of these
inflammatory markers have been associated with the development and
reoccurrence of cardiovascular disease73,74. Initially, many of these cytokines
were believed to be merely circulating markers of cardiovascular disease, but
recently there has been awareness of a potential mediating role in the initiation
and progression of atherosclerosis and neointima formation. Interesting support
for this assumption is provided by the current attention for C-reactive protein
(CRP). CRP is an acute phase reactant that is markedly increased after
inflammation, infection and surgery, but promptly returns to baseline levels
with resolution of disease75. Elevated levels of CRP have been associated with
recurrent events in patients with preceding cardiovascular disease76, but also
with the risk of isolated events in men and women without a history of
cardiovascular disease77,78. Further, CRP has been put forward as a prognostic
marker for restenosis following percutaneous coronary intervention79, and
recurrent ischemia after coronary bypass graft surgery80.
The ability of CRP to induce the release of proinflammatory cytokines by
endothelial cells, SMCs, and macrophages further emphasizes its candidature
as culprit mediator of cardiovascular disease81,82,83. CRP also facilitates the
inflammatory process by upregulation of adhesion molecules (e.g. ICAM-1) and
MCP-1 on endothelial cells84, which enhances monocyte/macrophage
recruitment into the vascular wall (see above). Taken together, CRP can no
longer be seen solely as an innocent predictor of cardiovascular disease, but
has surely been exposed as a true partner in crime. 
Initial suggestion of direct involvement of micro-organisms in the
pathogenesis of vascular disease dates from the late eighteen hundreds, when
Gilbert and Lion linked Bacillus typhosus to atherosclerotic disease85. Of great
importance for our current interest in the involvement of micro-organisms in
cardiovascular disease was the finding by Saikku et al who demonstrated the
17
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relation between Chlamydia pneumoniae (Cpn) infection and coronary artery
disease for the first time86. Many other seroepidemiological studies followed,
with the majority of them finding a positive relation between Cpn and the
development and progression of atherosclerosis87,88,89, but also some negative
seroepidemiological studies emerged over the last few years90,91. Further
disagreement over the role of Cpn in cardiovascular disease comes from
histological studies trying to locate Cpn in atherosclerotic plaques and
occluded vein grafts. Although several studies demonstrated the presence of
Cpn in various atherosclerotic intimal hyperplastic lesions using a variety 
of detection techniques92,93,94,95, the significance of this finding in the
pathogenesis of atherosclerosis was argued in the “innocent bystander”
hypothesis. This states that although Cpn might be present in atherosclerotic
plaques, presumably by transport in circulatory monocytes from the lung, it
would merely be a secondary passenger without pathological implication in
atherosclerotic disease, something that again has been refuted by others96.
Presently, the quarrel about the role for Cpn in cardiovascular disease is
stretched by results from interventional studies trying to eradicate Cpn from the
vasculature by antibiotic therapy to prevent cardiovascular events97,98,99,100. In
succession to Cpn, several other viral and bacterial pathogens (Herpes simplex
virus, cytomegalovirus, helicobacter pylori) have been linked with vascular
pathology101, but an indisputable role for these and other pathogens in (venous)
neointimal formation could not be confirmed thus far102,103.   
It is nevertheless possible that infection with micro-organisms before,
during or after venous bypass surgery may exert unfavorable effects on
endothelial function and bypass patency. For example, endothelial cells express
a variety of Toll-like receptors (TLR) on their surface, capable of recognizing
diverse molecules derived from bacteria, viruses and fungi. To date, 10 TLR
family members have been identified, of which endothelial cells predominantly
express TLR4 and little TLR2, which both respond to bacterial products (i.e.
lipopolysaccharides, peptidoglycans) by NF-ΚB activation and subsequent
increased gene expression of several chemokines, cytokines, adhesion
molecules, thus boosting the inflammatory response104. Furthermore, TLR
signaling has been implicated in arterial remodeling and neointimal
formation105,106. Interestingly, mycobacterial HSP60 also is recognized by TLR2
and TLR4, and due to molecular mimicry both human and mycobacterial
HSP60 may thus signal through TLRs to exert an inflammatory response107. The
high sequence homology between microbial and human HSPs could have
additional implications in vascular pathology, by cross-reactions of antibodies
and T cells against HSPs of microbes and humans. Consequently, human anti-
18
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HSP60 antibodies might react with HSP60 on the surface of stressed
endothelial cells (see above), thereby inducing a cytotoxic response and lyses
of the endothelium108. The rationale for this mechanism in vivo has been
supplied by serological studies demonstrating an association between serum
antibodies against microbial and human HSP and atherosclerotic disease109.
This mechanism of bacterial pathogen involvement in vascular disease was
later stressed by Mayr et al. who demonstrated that anti-mycobacterial
HSP60/65 antibody levels correlated strongly with human IgA to Cpn and with
IgG to Helicobacter pylori110.   
Role of smooth muscle cells in venous remodeling  
As mentioned above, venous intimal thickening after vein graft implantation is
mainly caused by an increase of SMCs in the intima of the vein by migration
from the media and sustained proliferation, followed by extracellular matrix
accumulation111. SMCs in the media of normal adult veins proliferate at a very
low rate (<0.1%/day), exhibit minimal synthetic activity, and express distinct
proteins and cellular structures sustaining the contractile phenotype of the
SMC. However, unlike some other cells of the cardiovascular system (i.e.
cardiomyocytes) that are terminally differentiated, SMCs can switch very
rapidly from quiescence to a proliferative state in response to appropriate
stimuli112,113. This so called plasticity of vascular SMCs is physiologically
important during morphogenesis of the blood vessel, when SMC proliferate,
migrate, and produce extracellular matrix components like collagen, elastin,
and proteoglycans, while at the same time acquiring contractile capabilities114.
Adversely, in a changed hemodynamic environment (e.g. arterial flow) the high
degree in plasticity of venous SMCs gives rise to a pathological synthetic and
proliferative phenotype. In addition, altered regulation of genes for several
extracellular matrix molecules, proteases and inflammatory cytokines enhances
and facilitates the process of intimal thickening115,116. This type of SMC
differentiation is generally referred to as “phenotypic modulation”, and is a pre-
requisite for migration and proliferation of SMCs during the development of
venous neointima formation117,118. 
Migration of smooth muscle cells
Mechanisms of SMC migration in the pathogenesis of venous neointima
formation are poorly understood. Extensive research revealed numerous
potential mediators, but as yet no common signaling pathway for migration has
19
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been presented. Environmental factors that have been discussed earlier obviously
are important mediators of chemoattractant signaling by vascular and blood
derived cells. One of the most potent chemoattractants is PDGF which is
produced by activated platelets, macrophages, and endothelial cells and
stimulates SMC migration in vein grafts119. PDGF expression is elevated during
the first week after vein graft surgery, but gradually returns to its baseline levels
by the fourth week postoperatively, which is in concert with the progress of
neointima formation that ceases to continue 4 weeks post-operatively. Further
evidence of a significant role for PDGF in venous intimal thickening was
supplied by Peppel and coworkers who found that inhibition of PDGF receptor-β
signaling reduced intimal hyperplasia in autologous vein grafts120. In addition
to PDGF several other cytokines like TNF-α, basic fibroblast growth factor
(bFGF), insulin like growth factor (IGF) I and II, and VEGF have pro-migrating
effects on SMCs, either autonomously or, more often, synergistically. For
example, TNF-α and PDGF have been shown to promote migration of SMCs
independently, but both common and complementary signaling mechanisms
contributed to an increased effect when SMCs were stimulated with PDGF and
TNF-α additively121. Reports on the effect of bFGF on SMC migration have been
more conflicting. Jackson et al122 found that SMC migration was enhanced by
bFGF in an artery injury model and that this effect could be neutralized with a
blocking antibody against bFGF, which is in disagreement with a study from Mii
and coworkers123 who reported an anti-migratory effect of bFGF. Explanation
for this discrepancy can be found in the assumption that the effect of bFGF is
dependent on the type of receptors present. The type II receptor is particularly
associated with inhibitory responses, and this type of receptor is lost in SMCs
found in atherosclerotic lesions, thus promoting intimal thickening124. IGF-I
and IGF-II share substantial homology with each other, are mainly produced in
the liver and constitute important metabolic functions125. However, IGF is also
produced by many other cells of the human body and locally produced IGF
may act as an autocrine and paracrine factor. Especially the role of IGF-I as a
potent stimulus of SMC migration and subsequent arterial neointima formation
is commonly acknowledged126,127.  VEGF is strongly induced in endothelial
cells by hemodynamic stress as well as inflammatory mediators and directly, or
indirectly through the induction of other growth factors, increases SMC
migration128,129. Although research on the effects of bFGF, IGF-I, and VEGF on
venous SMC migration is scarce, the described mechanisms may not differ
significantly for venous neointima formation. 
Triggering SMCs to exit the media and enter the intima in response to
aforementioned chemoattractants is facilitated by the degradation of
20
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extracellular components, which normally support SMCs to remain in a
quiescent state. The integrity of the extracellular matrix is largely determined by
the balance between production of matrix degrading MMPs, the inhibitors of
MMPs or TIMPs, and matrix deposition by SMCs130. In nondiseased human
veins, MMP-2 and TIMP-1 and TIMP-2 are constitutively expressed at levels
providing a stable balance between endogenous matrix production and matrix
degradation57. MMPs are produced by different vascular and blood-derived
cells that play a part in venous intimal thickening, mostly in response to
cytokines and other growth factors. For example, MMP-9 production by
monocyte derived macrophages is enhanced after stimulation with TNF-α and
IL-1β131. In contrast, other cytokines like IFN-γ, IL-4, IL-6, and IL-10 have been
reported to reduce MMP production132,133. Local MMP-9 secretion by medial
venous SMCs significantly adds to MMP-9 release by inflammatory cells, and
has also been found to be increased by growth factors like PDGF, TNF-α, and
VEGF134,135,136. 
Environmental (e.g. hemodynamic stress) cues contribute to phenotypic
switching of SMCs into a synthetic phenotype, stimulating the expression of
MMP-2 and MMP-9, favoring matrix degradation, SMC migration, and
subsequent intimal thickening that leads to graft failure61,137,62,18. Further
evidence for MMP involvement in venous neointima formation was supplied by
the finding that a synthetic MMP inhibitor drug reduced intimal hyperplasia in
a vein graft model138. In contrast to the upregulation of MMPs, their
endogenous inhibitors, TIMPs do not seem to be differently expressed in vein
grafts by hemodynamic or surgery-related stress, consequently disturbing the
MMP-to-TIMP ratio in favor of MMPs139,62. However, overexpression of TIMP-
1, TIMP-2, and TIMP-3 by adenovirus-mediated gene transfer independently
inhibited SMC migration and neointimal formation in vein grafts, suggesting an
important role for TIMP regulation in venous neointima formation140,141,142. 
Proliferation of smooth muscle cells
Normal vein SMCs are quiescent and phenotypic modulation is inhibited
mainly through cell-matrix interactions, interactions between basement
membrane components and cell surface integrins, and soluble mediators, thus
restraining SMC proliferation118,143,144. Quiescent SMCs are reserved in the G0
phase of the cell cycle where mRNA and protein synthesis are retained to a
minimum, and cellular activity is mainly in support of contractile function. On
stimulation, SMCs may recommence progression through the cell cycle at the
first gap (G1) phase and regenerate mRNA and protein synthesis necessary for
DNA replication that takes place during the S phase. Subsequently, the second
21
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gap (G2) phase is entered to produce proteins that are required for the final (M)
phase during which the cell divides into two daughter cells. During cell cycle
progression two checkpoints have to be passed to ensure that cell division
proceeds normally. When the first checkpoint (G1-S transition) is passed, the
cell reaches its “point of no return” and is committed to continue cell cycle
progression, DNA synthesis, and cell division. However, the second checkpoint
(G2-M transition) might still prevent mitosis when incomplete or damaged DNA
replication has occured145. During SMC cycling, progression through the
different transition points and checkpoints is tightly regulated by a group of
regulatory molecules consisting of cyclins, cyclin-dependent kinases (CDK) and
their restricting molecules, the cyclin-dependent kinase inhibitors (CKI)146. The
mammalian cell cycle and its complex mechanisms have been excellently
reviewed before147, thus discussion of the cell cycle machinery will be
confined to the mechanisms related to SMC proliferation and intimal
hyperplasia. Briefly, cyclin-dependent kinases (CDK1-7) specifically bind with
22
Chapter 1
Figure 3.
Diagram showing the progression of the mammalian cell cycle and the relationship between
regulatory molecules involved in cell cycle control.
cyclins (cyclin A-H) to form active complexes able to stimulate cell cycle
progression through the different phases. In the quiescent cell though, these
complexes are negatively regulated by a family of CKIs (p15, p16, p18, p19,
p21, p27, p57)146,147, that in turn assembles an inactive complex. This
equilibrium can exist for a very long time, but is instantly lost when the cell is
triggered by mitogenic stimuli like cytokines and other growth factors. Essential
for the subsequent cell cycle progression is the transcription factor E2F, that
appears ineffective in the G0 phase because it is bound to the retinoblastoma
protein (Rb), which is expressed throughout the entire cell cycle148. The ability
of Rb to suppress E2F activity is phosphorylation dependent, and will only
occur in its hypophosphorylated state148. However, mitogenic factors can start
off a signaling cascade that result in disintegration of the cyclin/CDK/CKI-
complex, a subsequent hyperphosphorylation of the Rb product, thereby
releasing E2F, that in turn regulates transcription of several genes necessary for
cell division (Figure 3).     
The significance of cell cycle molecule expression and vascular disease
has recently been established. p27, one of the most commonly expressed CKIs,
was found upregulated in SMCs during serum deprivation, leading to arrest in
the G1 phase of the cell cycle, supposedly by binding of p27 to cyclin E/CDK2
complexes in these cells149. Conversely, p27 protein levels decrease drastically
after arterial balloon injury, parallel to SMC proliferation levels and progress of
intimal thickening during 3 weeks post injury149. Additional reports clearly
show the association between cell cycle protein levels and SMC growth
responses. For instance, while SMC growth inhibition correlates to high levels
of p27150,151, growth factor induced SMC proliferation corresponds with
decreased p21 and p27 expression152.   
Cell cycle progression and subsequent SMC proliferation in response to
growth factors is of great importance in neointimal formation, and involves both
paracrine and autocrine growth regulation. The potency of PDGF, bFGF, and 
TGF-β on SMC proliferation has been discussed above. The most potent other
stimuli of SMC proliferation will be discussed beyond. IL-1 is produced by
activated macrophages within the blood vessel wall, but also by SMCs themselves
when stimulated in vitro with proinflammatory cytokines153, and is a particularly
effective mitogen, markedly stimulating SMC proliferation upon chronic
exposure154,155. Consequently, IL-1 has been proposed to contribute to neointimal
hyperplasia in saphenous vein grafts after coronary bypass surgery, since
immunoreactive IL-1 was found in SMCs of stenotic vein grafts but not in internal
mammary arteries that had remained patent and in normal arteries and veins156.
In addition to its role in SMC migration, IGF also effectively regulates vascular
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SMC proliferation in vitro and in vivo157,158. Furthermore, increased IGF-I gene
expression after arterial injury resulted in enhanced neointimal formation
through increased proliferation of SMCs127. Additionally, several other
cytokines (e.g IL-6, IL-8, TGF-β) induce direct SMC proliferation or indirect
SMC proliferation by growth factor induction in SMCs, thereby provoking an
autocrine growth response (reviewed by Berk159). 
SMC migration and proliferation as just described are very important
processes in the development of venous intimal hyperplasia. It should be noted
however, that SMCs derived from preexisting medial SMCs are probably not 
the only cells that can be retrieved in venous intimal thickenings.
Transdifferentiation of ECs and adventitial fibroblasts into SMC-like cells might
also add to venous neointima formation. However, since the generally used
markers of SMC lineage lack specificity, it remains virtually impossible to
discriminate between preexisting SMCs and SMC-like cells, making the relative
contribution of these cells to neointima formation unclear. Moreover, recent
research suggests that also bone marrow derived cells contribute to intimal
thickening by giving rise to cells that express at least some properties of
vascular SMCs160,161. However, the arterial injury model used to investigate
these new insights can hardly be used to elucidate the process of venous
neointima formation. Sata et al160 described a model in which severe injury was
inflicted on the vascular wall, causing total loss of the endothelium and
extensive medial SMC apoptosis. Han et al161 previously had shown that a
relatively mild injury did not cause recruitment of any bone marrow cells into
the denudated vascular wall. Furthermore, even if bone marrow derived cells
do invade the vasculature in case of injury, it is very doubtful that these cells
undergo differentiation into mature SMCs114.     
Prevention and intervention of neointima formation in vein grafts  
Well established risk factors in atherosclerotic disease have also been shown to
have adverse effects on vein graft patency. Smoking is a risk factor for both early
and late graft failure as a result of thrombosis and late atherosclerotic
deformation162,163. Cessation of smoking within 6 months of bypass surgery
resulted in significant higher graft survival rates at 10 years post-surgery164.
Interestingly, another prospective follow-up study showed similar outcome
results between patients who stopped smoking after surgery and nonsmokers,
although both groups had a significant lower risk of cardiovascular events
compared to persistent smokers165. Dyslipidemia (e.g. high cholesterol, LDL,
and triglyceride levels and low HDL levels) has consistently been related to late
graft atheroma development as it has been related to native arterial
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atherosclerosis before166,167. The lack of association between hyperlipidemia
and early graft failure is probably due to absence of atherosclerotic vein graft
lesions in the first years after bypass surgery168. The importance of lipid
lowering treatment to prevent vein graft disease has been established by two
trials showing that aggressive cholesterol lowering therapy by statins markedly
reduced cardiovascular events and need for revascularization169,170. Likewise,
since hemodynamic stress has extensively been related to endothelial
dysfunction and arterial and venous intimal thickening (see above), it seems
reasonable that systemic hypertension is related to the development of venous
intimal hyperplasia. However, to date systemic hypertension has not been
considered a risk factor for venous intimal hyperplasia171. Nonetheless,
prevention of endothelial dysfunction has been proven by oral aspirin
administration72,172, which is also beneficial in the prevention of platelet
aggregation, another culprit mechanism in vein graft disease. However,
contradicting results of studies demonstrating the effect of aspirin on venous
graft patency suppress the justification for long-term aspirin administration to
prevent vein graft disease173,174.
The most promising intervention to prevent neointimal formation at this
moment is probably cell cycle interference, for instance by local or systemic
application of synthetic drugs like sirolimus and paclitaxel.
Following the success of anti-proliferative drug application in the
prevention of restenosis after coronary PTA175,176, local release of these drugs
also showed to reduce intimal thickening in vein grafts177,178. The finding that
oral administration of sirolimus reduced restenosis after treatment of in-stent
stenosis179 may have important implications in the prevention of neointimal
formation in vein grafts. Another possibility that has been successfully
employed in preventing intimal thickening by SMC cell cycle blocking is
through adenovirus mediated gene delivery into the grafted vein180, but the
danger of mutations hamper their safety and efficacy181. 
In conclusion, neointimal formation in vein grafts is a multifactorial process,
which up to now made it impossible to isolate a single mechanism suitable for
interventional targeting, thus ensuing increased patency in vein grafts.
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Aims of the study
The role of inflammation in vein graft pathology has been widely established.
Inflammatory cells are proven to enter the vessel wall rapidly after
implantation182. It is believed that endothelial injury caused by hemodynamic
stress results in upregulation of adhesion molecules. Hereby, influx of
inflammatory cells is facilitated and subendothelial localization of activated
cells develops. Subsequent secretion of cytokines stimulates SMC migration
and proliferation leading to intimal hyperplasia. Although the pathogenesis of
vein graft disease has predominantly been revealed, it remains unclear why
certain vein grafts are committed to early failure, while others remain patent for
many years. It would be of great value if one could predict the destiny of vein
at the time of implantation. Anti-inflammatory treatment might thus be
employed in specific cases to avert the detrimental events leading to vein graft
failure. Earlier it has been suggested that morphological differences between
native veins underlie variations in patency rates. In concord we wish to assess
inflammatory cell compound in native veins used for bypass grafting and relate
the inflammatory profile to patency rates.    
As mentioned above hemodynamic stress has indisputably been
implicated in vein graft pathology. However, we believe that additional
characteristics of the arterial circulation may facilitate vessel wall injury, and
need to be considered in the pathogenesis of vein graft disease.  However, the
cascade leading to SMC activation and proliferation is still open for
investigation. Autologous HSP60 induction is directly stimulated by high cyclic
stress and has been implicated in immunology related processes in the vascular
wall. Due to high homology between HSPs, cross reaction between
endogenous and exogenous HSP60 activate cells of the immunity system and
induce inflammatory processes. Furthermore, exogenous HSP60 has been
proven to induce SMC proliferation by signaling through Toll Like Receptors
(TLR). We propose that endogenous HSP60 may also induce venous smooth
muscle proliferation by interaction with TLR2 and 4. 
Hemodynamic stress has clearly and beyond doubt been implicated in the
pathogenesis of vein graft disease. Naturally, venous endothelial cells are not
used to arterial flow and thus endothelial injury and dysfunction is likely to
occur, proven by ample former research. Another typical difference between
arterial and venous circulation is the high oxygen tension in arteries as
compared to veins. Interestingly however, as yet no studies have been
presented on the possible negative effects of supra-physiological oxygen levels
on venous cells and vein graft survival. We want to assess the influence of
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hyperoxia on venous cells and examine the effect of antioxidant treatment on
oxygen stressed cells and venous neointima formation.
Ultimately, it is the final common pathway of cell cycle progression that
determines whether exposure to pro-mitogenic agents lead to proliferation, and
therefore, in theory would be an excellent candidate for intervention. As
mentioned above, cell cycle progression is determined by the balance between
CDKs and CKIs. It has become clear that a certain temporal expression of these
cell cycle regulators exist in the process of venous intimal hyperplasia. For
example, it has been shown that p27, a holoenzyme which blocks cell cycle
progression, is upregulated in the latest phase of intimal hyperplasia. As for the
temporal expression of p21 some conflicting data has been presented.
However, at the time of clinical failure, it is not evident how cell cycle
regulators are interrelated. Therefore, we propose a study in which the
expression of cell cycle proteins will be examined, basically to find a possible
target for intervention.   
Recently, an immune suppressive drug, FK778 has been suggested to
exhibit anti-proliferative aspects and has been put forward to attenuate arterial
restenosis in an animal model. As mentioned above, we believe that
pharmacological intervention might be highly effective when directed at the
final common pathway of venous SMC proliferation. The mechanisms of FK778
have been suggested to involve the de novo synthesis of pyrimidine. Without a
sufficient pool of pyrimidine, cell cycle locomotion will discontinue in the late
G1 phase. Therefore, we suggest that FK778 might be a promising drug to
inhibit venous neointima formation.    
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Presence of inflammatory cells 
in saphenous veins used for
peripheral bypass surgery predicts
early graft failure
Abstract
Background. Intimal hyperplasia (IH), characterized by smooth muscle cell
accumulation and extracellular matrix deposition in the intima of grafted veins,
is the major cause of infra-inguinal graft failure in the first post-operative year.
Recent evidence suggests that these changes may be driven by inflammatory
cytokines. Furthermore, preexisting saphenous vein disease has been associated
with decreased graft patency. We evaluated the presence of inflammatory cells
in failed venous bypass grafts and studied the effect of preexistent saphenous
vein inflammatory cell accumulations on bypass graft failure.
Methods. Specimens (n=15) of failed saphenous vein grafts were harvested
from fifteen patients (8 men and 7 women; mean 59.8 years) during bypass graft
revision surgery. Left-over segments (n=17) of saphenous veins used as
infrainguinal grafts, harvested during surgery, formalin fixed and paraffin
embedded were retrieved from the histological archive of Maastricht University
Hospital. By cross checking the clinical notes and vascular laboratory
assessments, it was ascertained that 9 of these grafts remained open for longer
than one year (nDIH = not developing IH), whereas 8 grafts restenosed/
occluded within one year after implantation (DIH = developing IH). The
presence of macrophages, B-lymphocytes and T-lymphocytes in the occluded/
stenosed bypass grafts and the left-over segments was assessed
immunohistochemically.
Results. IH lesions of failed vein grafts exhibited a significantly higher number
of T-cells and macrophages compared to left-over saphenous vein segments.
Among these vein segments, a significantly higher number of both macrophages
and T-lymphocytes was present in those veins that subsequently stenosed/
occluded within 12 months after implantation as vein-graft. Except for gender,
the prevalence of risk factors for graft occlusion (age, hypertension, smoking,
diabetes and level of distal anastomosis) was similar in both groups.
Conclusion. T-cells and macrophages are abundantly present in IH lesion of
vein-grafts. Furthermore, early presence of T-cells and macrophages in veins
used as bypass grafts is associated with graft failure. This observation suggests
that preexistent inflammatory changes in veins render them susceptible to
develop advanced IH when implanted as vein-grafts. Thus, the presence of 
T-cells and macrophages in veins used for infra-inguinal revascularization
might be a valuable a priori marker of graft failure. Such a marker could allow
tailored graft monitoring and preventive medical (anti-inflammatory) treatment
schemes.
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Saphenous vein graft disease consisting of thrombosis, intimal hyperplasia or
atherosclerosis is associated with decreased graft patency limiting the
therapeutic effect of this surgical revasularization procedure in the treatment of
arterial obstructive disease. Intimal hyperplasia (IH), characterized by vascular
smooth muscle cell (VSMC) accumulation and extracellular matrix deposition
in the intima of the grafted vein, is a major cause of venous graft failure
between 1 month and 1 year after implantation1. In analogy to atherosclerosis,
it is increasingly being appreciated that inflammatory processes may play an
important role in the development of IH as well2,3. The arterial shear and
circumferential stresses to which the grafted vein is exposed to, as well as the
endothelial damage caused by surgery, triggers venous cellular activation
leading to an inflammatory response that might contribute to intimal
hyperplasia4. This response starts with induction of adhesion molecule
expression on VSMCs and endothelial cells (ECs), monocyte adhesion and
extravasation into the vessel wall1. Initially, leukocytes (e.g. monocyte derived
macrophages and T-cells) are drawn towards the injured vascular wall by
chemotactic factors, among others, the very potent monocyte chemotactic
protein-1 (MCP-1). MCP-1 is secreted by SMCs5, fibroblasts6, and shear stressed
ECs7, and is associated with the development of intimal hyperplasia in vein
grafts8. Recruitment of T-cells and macrophages has been strongly implicated in
the initiation and amplification of the inflammatory response leading to IH9.
Upon activation, macrophages secrete cytokines, chemokines, growth-regulating
molecules and metalloproteinases (MMPs)10. Furthermore, activated macrophages
are capable to present antigens to T-cells which trigger cell-mediated immune
responses11. Consequently, T-cell activation results in the secretion of cytokines,
including interferon-y and tumor necrosis factor, which amplifies the
inflammatory response, and aggravates IH12. Although it is widely accepted that
inflammatory processes play a significant role in IH development, it is unclear
how inflammatory activity relates to the extent of IH and therefore bypass
patency. Both in situ as well as systemic inflammatory processes may be
involved in the development of IH. Non-specific, systemic innate immune
responses have been implicated in the development of intimal hyperplasia13.
Therefore, preexistent activation of the immune system at the time of bypass
surgery might hamper graft survival14. In-situ inflammatory processes might 
also facilitate disproportionate IH development. Wali et al showed that
inflammatory cells are present in normal appearing veins used for arterio-
venous fistula construction and co-localize with microscopic degenerative
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changes in the vessel wall15. Furthermore, is has been shown that preexisting
vein disease is a cause of venous bypass failure16. 
In the first part of the present study we observed that IH lesions of
stenosed/occluded vein grafts were more densely populated by macrophages
and T-cells compared to native veins. Considering the pronounced involvement
of inflammatory cells in the development of IH and the assumption that
preexistent pro-inflammatory changes within the saphenous vein might
represent a higher risk of early vein graft failure, we wanted to see whether the
simple presence of inflammatory cells within the saphenous veins is related to
early bypass failure.
Patients and methods
Specimens (n=15) of failed venous bypass grafts were harvested from fifteen
patients (8 men and 7 women; mean 59.8 years) during venous bypass graft
revision at the surgical department of Maastricht University Hospital. Failure of
bypass grafts was suspected on clinical ground (clinical evaluation, ankle-arm
index <90), and verified by high-grade stenosis or occlusion on angiography.
The stenosed or occluded segment of the failed bypass grafts was formalin-fixed
and paraffin embedded.
Left-over segments of greater saphenous veins were obtained from 17
patients (10 male, 7 female), undergoing autologous venous infra-inguinal
bypass graft surgery for critical limb ischemia. The average age of the patients
was 67.2 years (range: 49 - 80 years). The suitability of the vein as bypass graft
was assessed by means of pre-operative ultrasound scan and per-operative
macroscopic evaluation. Only veins of adequate size and macroscopically free
of pre-existent disease (varicose, calcifications, occlusion) were actually used
as bypass grafts. After explantation, the left-over vein segments were
immediately perfusion-fixed at 100 mm Hg in 4% formalin for 4 hours,
followed by 18 hours in 70% ethanol, and finally paraffin-embedded for
morphometric and immunohistological analyses. 
The study was approved by the Medical Ethical Committee of Maastricht
University Hospital and conformed with the principles outlined in the
declaration of Helsinki17. All patients entered the study after giving written
informed consent.
Immunohistochemistry
The failed bypass graft and left-over vein segments were cut in 4 μm thick slices,
48
Chapter 2
deparaffinized and rehydrated by subsequent washing in xylene, 100% EtOH,
70% EtOH, 50% EtOH and phosphate buffer. Sections were stained with
hematoxilin-eosin (HE) and Lawson for routine histology and morphometric
analyses or were used for immunohistochemical analyses. 
The cellular composition of stenosed bypass grafts and non-diseased left-
over veins was assessed using anti-smooth muscle actin and anti-von Willebrand
factor antibodies for detection of smooth muscle cells and endothelial cells,
respectively. For the detection of inflammatory cells anti-CD68 (macrophages),
anti-CD20 (B-lymphocytes), and anti-CD3 (T-cells) antibodies were used. Antigen
retrieval was carried out by boiling in citrate buffer, pH 6.0. Prior to staining
aspecific binding sites were blocked by incubation with mouse ascitic fluid in 2%
BSA/TBS/tween for 20 minutes. After washing in Tris buffered saline the sections
were immunohistochemically analyzed for presence of macrophages, B- and T-
cells by incubation with anti-CD68 (Dako M0814), anti-CD20 (Dako M0755),
and anti-CD3 (Dako M7254) antibodies respectively. Primary antibodies were
diluted in TBS and applied to the slides for 60 minutes at room temperature. After
3 washes with TBS for 5 minutes, a biotinylated horse anti-mouse secondary
antibody (1:400 dilution, Dako) was applied for 30 minutes at room temperature,
followed by a steptavidin amplification reagent (Dako) for 30 minutes at room
temperature. Finally, Fast Red was used for 10 minutes at room temperature,
yielding a red reaction product. Visualization of all nuclei in the tissue sections
was realized with a haematoxylin counterstain. The incidence of CD3 positive T-
cells, CD20 positive B-cells and CD68 positive macrophages was determined 
by means of a microscope-based video image analysing system (Analysis®, Soft
Imaging System, Münster, Germany) at a 10 x 40 magnification. Direct
quantification was done by counting total immunoreactive macrophages, B- and
T-cells in the entire section. For reasons of practicability semi-quantification
analysis was performed to determine immunoreactive T-cells. 
Statistical analysis
Data are expressed as mean values and standard errors of the mean (SEM).
Statistical significance was evaluated by the non-parametric Mann-Whitney U
test for independent groups using the SPSS 10.0 package for Windows (SPSS,
Chicago, Ill., USA).
Results
All failed bypass graft sections showed considerable neointimal areas and
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increased intima-media thickness as compared to native saphenous veins.
None of the removed bypass grafts failed as a result of acute thrombosis as
determined by visual inspection and microscopic evaluation. Anti-α-smooth
muscle actin staining revealed smooth muscle cells as the main cellular
component of the neointima. 
Immunostaining against macrophages on non-diseased veins showed
limited amounts of CD68 positive cells. In contrast, we observed an overwhelming
increase in the number of macrophages in intimal hyperplastic lesions of
stenosed venous bypass grafts. Moreover, the amounts of T-cells in failed
venous bypass grafts were significantly higher throughout the examined vessel
compared to normal veins (Table 1). However, variable distribution throughout
the vessel wall was obvious. T-cells and macrophages were infrequent in the
intima, while the adventitia showed apparent higher levels of T-cells. More
interestingly, remarkable disparity in macrophage and T-cell load were seen
amongst normal veins. Therefore, we hypothesized that macrophage and T-cell
presence in saphenous veins before implantation as bypass grafts might be
related to attrition rate. Thus, we retrospectively assessed clinical outcome
(failed versus open vein graft) at 12 months post-surgery. Through cross checking
the clinical notes and vascular laboratory assessments, it was ascertained that 
9 venous grafts remained open for longer than one year, whereas 8 vein grafts
failed within one year after implantation. The mean survival time of the 
failed vein grafts was 5.8 ± 1.4 months. Veins that developed clinical significant
IH (DIH) did not show morphological differences (intima area, intima/media
thickness) at base line with veins that did not develop IH (nDIH). 
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Table 1.
Presence of macrophages, B-cells and T-cells in failed venous bypass grafts, vs normal veins. n.int, (neo)intima; med,
media; adv, adventitia.
Macrophages B-cells T-cells 
(N) (N) (scale: 0-4)*
n.int med adv total n.int med adv n.int med adv total
d d al
Failed bypass (n=15) 2.2 6.1 33 41 0 0 0 1.0 0.9 1.8 3.3
Normal veins (n=17) 0.4 0.6 8.9 9.4 0 0 0 0.2 0.4 0.6 1.4
P (Mann-Whitney) 0.54 0.35 .018 .015 - - - 0.12 0.19 .035 .023
(*) 0: 0-10 T-lymphocytes, 1: few T-lymphocytes, 2: moderate number of T-lymphocytes, 3: many T-lymphocytes s;
4: excessive number of T-lymphocytes.
Moreover, demographics between DIH and nDIH groups were compared and
no differences in incidence of diabetes, hypertension, smoking, cardiac- and
cerebrovascular disease were noticed. Immunhistochemical analyses revealed
significantly higher amounts of T-lymphocytes and macrophages in saphenous
veins that developed IH within one year than in the left over segments of vein
grafts that remained open for more than one year (figure 1 and figure 2). As
mentioned earlier for hyperplastic lesions from failed grafts, maximum
inflammatory cell localization was seen in the adventitia, but average medial T-
cell and macrophage count was also higher in DIH veins compared to nDIH
veins (figure 1 and figure 2). In contrast to macrophage and T-cell presence no
CD20 (B-cells) immunoreactivity was noticed in either native veins or intimal
hyperplastic lesions. These findings support the concept that inflammatory cells
might be involved in the development of IH.
Discussion
Following implantation in the arterial circulation venous conduits undergo a
sequence of events which in several cases result in infinite vein graft disease
and eventual failure. Initially, the development of a diffuse intimal thickening is
noticeable, which is followed by more pronounced intimal hyperplasia and
progresses to atheromatous plaque formation. In these more mature stages of
vein graft disease inflammatory cell deposits, in particular lymphocytes and
macrophages are clearly localized within the intimal hyperplastic lesion. The
present study analogously shows that intimal hyperplastic lesions are
characterized by accumulation of T-cells and macrophages supporting the
association between vein graft remodeling and influx of inflammatory cells.
However, over recent years it became clear that inflammatory cells not merely
localize in intimal hyperplastic lesions, but play an essential role in the
initiation and aggravation of vein graft attrition. MCP-1 expression and
subsequent monocyte infiltration have been associated with IH development in
vein grafts9,18.
The influx of leucocytes into the graft wall may be triggered by injury of
the vein during the surgical procedure (i.e. vein handling, warm ischemia and
reperfusion) or may be related to adaptation of the grafted vein to arterial flow
resulting in graft remodeling. Stark et al showed that monocytes infiltrate the
luminal surface from day 1 post-surgery and reside in the venous wall
thereafter19. Surprisingly, we found not only failed bypass grafts to express
inflammatory cells but saphenous veins before implantation as well.
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Figure 1.
Distribution of macrophages and T-lymphocytes in left over segments of saphenous veins
implanted as bypass grafts. A, average number of macrophages is significantly higher in the media
and adventitia of DIH veins in comparison with NDIH veins. B, semi quantification analysis*
showed significantly higher amounts of T-lymphocytes in the media and adventitia of DIH veins in
comparison with NDIH veins. NDIH veins: left-over segments of veins Not Developing IH as bypass
grafts; DIH veins: left-over segments of veins Developing IH as bypass grafts. * P< .05  
(*) 0: 0-10 T-lymphocytes, 1: few T-lymphocytes, 2: moderate number of T-lymphocytes, 3: many
T-lymphocytes s; 4: excessive number of T-lymphocytes. 
Inflammatory cell deposits in the venous wall prior to implantation have not
been described as yet. Although a relatively small group of veins was available
for research, we noticed a marked variability in inflammatory cell load between
different saphenous veins. Since mononuclear cells has been described in the
intima of non-atherosclerotic carotid arteries of children20 suggesting that a
local immune-mediated process may underlie the development of
atherosclerosis, we hypothesized that the early presence of inflammatory cells
in saphenous veins at the time of harvest and their implantation as grafts might
render these veins susceptible to develop excessive intimal hyperplasia leading
to graft failure. 
Interestingly, our data show that presence of T-cells and macrophages in
the intima/media of veins before implantation as bypass grafts is associated with
subsequent development of venous intimal hyperplasia, emphasizing the role
of local inflammatory mechanisms in the early stages of the development of
venous intimal hyperplasia. Firstly, this substantiates that inflammatory cells
might be involved in the development of intimal hyperplasia. Secondly, the
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Figure 2. 
Immunohistochemical representation of macrophage and T-lymphocyte distribution in failed
bypass sections and saphenous vein segments. A-C: abundant expression of CD3 immunoreactivity
(T-lymphocyte) in failed bypass graft segment (A), while T-cell presence in DIH vein segment is
clearly less pronounced. CD3 expression in NDIH vein segment (C) is virtually absent. D-F:
macrophages (CD68 immunoreactivity) mainly localize in the media and adventitia of failed bypass
graft segment (D). To a lesser extent, macrophages also are present in the media and adventitia of
DIH vein segments (E). Macrophage count is almost nil in NDIH veins (F). 
presence of T-cells and macrophages in veins used for infra-inguinal
revascularization might therefore be a valuable a priori marker of graft failure.
Such a marker could allow tailored graft monitoring and preventive medical
(anti-inflammatory) treatment schemes21.
The presence of inflammatory cells in saphenous veins might relate to pre-
existent degenerative disease like varicose or phlebosclerosis. However, except
for structural studies22, to the best of our knowledge no available studies
showed inflammatory cell contents in degenerative saphenous veins. Panetta et al16
already suggested that unsuspected preexisting saphenous vein disease is a
cause of vein bypass failure. As in the study form Panetta et al visual inspection
revealed no signs of vein disease in our patient group.
Except for gender, the presence of risk factors for vein graft disease (age,
hypertension, smoking, diabetes and level of distal anastomosis) did not differ
significantly between occluded and patent grafts. Only 1 of 8 patients with
occluded vein grafts was female compared to 6 of 9 patients with patent grafts.
Since female sex has been associated with increased incidence of graft
occlusion due to smaller caliber vessels22,23, diagnosis- and treatment-delay in
women, and presence of inflammatory cells in the vascular wall is not known
to be related to gender, it is unlikely that this factor has been a potential
confounder in our study. 
Concluding, our findings underscore the inflammatory nature of intimal
hyperplasia, and suggest that the early presence of T-cells and macrophages in
veins used as bypass grafts might be a predictive marker for vein graft
occlusion. This observation offers a potential means to select patients at risk for
graft failure allowing applying intensified monitoring and anti-inflammatory
treatment schemes to these patients.
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Human heat shock protein 60
stimulates vascular smooth 
muscle cell proliferation through
toll like receptor 2 and 4
Abstract
Objective. Heat shock proteins (HSP) from endogenous and exogenous origin
are suspected contributors to the initiation and aggravation of vascular
pathologies, like atherosclerosis and restenosis. Toll like receptor (TLR) 2 and 4
are well known receptors for exogenous pathogen-associated molecular
patterns and have recently been thought to play a role in HSP60 induced
cellular activation. We hypothesized that human HSP60 directly stimulates
venous smooth muscle cell (VSMC) proliferation through a TLR dependent
mechanism. 
Methods. Localization of HSP60, TLR2 and TLR4 was studied in failed venous
grafts and normal venous tissue by double immunostaining. In vitro VSMCs
were incubated for 48 hours with recombinant human HSP60. In other
experiments, VSMCs were pre-incubated for 30 minutes with specific anti-TLR2
and anti-TLR4 antibodies. VSMC proliferation was determined by Ki67
immunoreactivity and mean values were compared between experimental and
control groups. In addition, human embryonic kidney (HEK) cells transfected
with human TLR2 or TLR4/MD-2 were exposed for 48 hours to HSP60, and
proliferation was determined by using a hemocytometer.
Results. Co-localization of HSP60 and TLRs was detected in all neointimal
lesions but was virtually absent in normal veins. Human HSP60 stimulated
VSMC proliferation in a concentration dependent fashion. In addition, TLR 2
and TLR 4 antibodies attenuated VSMC proliferation. The role of TLR-mediated
stimulation of cell proliferation by HSP60 was supported by the significant
increase in proliferation of transfected HEK cells. 
Conclusions. These findings provide supporting evidence for the role of HSP60
and TLR2 and 4 in vascular disease. Moreover, our data surpass the infection
and autoimmunity based hypothesis of cardiovascular disease and suggests an
additional HSP60-related autocrine process.  
Keywords: Toll like receptor; heat shock protein; neointima
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Introduction
Intimal hyperplasia (IH), mainly characterized by venous smooth muscle cell
(VSMC) migration and proliferation, contributes significantly to venous graft
failure and atherosclerosis1. Although both processes have been studied
extensively, the exact mechanisms are still unknown. Until the 1990s, most
research focused on the role of various cytokines, growth factors and their
cognate receptors. More recently, heat shock proteins (HSPs) emerged as
possible culprits to cardiovascular disease2. Altered hemodynamic conditions,
like those found in venous bypass grafts and atherosclerosis prone sites of the
vascular tree, as well as high levels of oxidized low-density lipoproteins are
possible causes of HSP induction3-4. In addition, microbial agents (eg
Chlamydia pneumoniae) induce the production of bacterial as well as the
endogenous HSP production by (vascular) host cells5, 6. Indeed, Chlamydia
HSP60 co-localizes with human HSP60 within atherosclerotic plaque
macrophages7. Initially, it was found that serum levels of antibodies against
human and mycobacterial HSP60 markedly correlated with cardiovascular
disease8-9. Succeeding research showed that soluble HSP levels are associated
with intima-media thickness and early atherosclerosis10. Kol and colleagues
were the first to demonstrate that human HSP60 activates human endothelial
cells, smooth muscle cells, and monocyte-derived macrophages11 thereby
providing a potential link between HSP and vascular disease. Furthermore,
endogenous as well as exogenous HSP60 have been implicated in vascular
smooth muscle cell proliferation6, 12. Most evidence suggests a central role for
Toll-like receptors (TLRs) in HSP related cellular signaling. Like HSPs, TLRs are
conserved through evolution. Of the 10 identified human TLRs, TLR2 and TLR4
are generally believed to be involved in the pathogenesis of cardiovascular
disease13-14. TLR2 and 4 are expressed in most cardiovascular cells, like
endothelial cells15, smooth muscle cells13 and macrophages16. Activation of
these cells as a response to self and non-self ligands appears to be mediated by
TLR2 and 417-18. 
However, human HSP60 induced VSMC proliferation, and the role of
TLR2 and 4 herein, has not been investigated yet. In the present study, we first
localized HSP60, TLR2 and TLR4 in venous neointimal lesions. In addition, we
determined the effect of human HSP60 on VSMC proliferation and the
mediating potency of TLR2 and TLR4 blockers in this process. Moreover, as a
proof of concept, we determined whether HSP60 is able to enhance cell
proliferation of HEK cells stably transfected with either TLR2 or TLR4/MD2.
61
HSP60 stimulates venous SMC proliferation
Methods
Reagents
Recombinant human HSP60 proteins were purchased from StressGen
Biotechnologies Corp. (Victoria, British Columbia, Canada). This preparation
(catalog no. ESP-540) was low in endotoxin as determined using Limulus
Amebocyte Lysate (LAL) assay. Functional grade purified mouse-anti-human
Toll-like receptor 2 and 4 (clone TL2.1 and HTA125 respectively) antibodies
were obtained from eBioscience (San Diego, CA, USA). Monoclonal anti-Ki67
antibody was obtained from DakoCytomation, Denmark. Human embryonic
kidney (HEK) cells stably transfected with human TLR2 or TLR4/MD-219 were
kindly provided by Dr. Golenbock (Worcester, MA).
Cell culture
Venous smooth muscle cells were obtained from ATCC (Manassas, USA), and
cultured in F-12K medium (Kaighn’s Modification of Ham’s F-12 Medium),
supplemented with 0.1 mg/ml heparin, 0.03 mg/ml endothelial cell growth
supplement (ECGS), and 10% fetal calf serum. Passages 4-6 were used for
experiments. 
Transfected HEK cells were grown in Dulbecco’s Modified Eagle Medium
(Gibco, Grand Island, NY) with 10% fetal calf serum (FCS). HEK cells stably
transfected with the empty vector pcDNA were used as control cells.
Immunohistochemistry
Eight samples of failed venous grafts were obtained from patients undergoing
arteriovenous fistula revision at the surgical department of the University
Hospital Maastricht. During revision, the stenotic lesions were removed and
fixed in 10% formalin for 4 hours, followed by 18 hours in 70% ethanol, and
paraffin-embedded for immunocytochemistry. Paraffin sections were incubated
in 2% BSA/PBS/tween for 20 minutes to block aspecific binding activity. TLR2,
TLR4, and HSP60 antibodies were diluted in 2% BSA/PBS and applied to the
slides for 60 minutes at room temperature, followed by biotinylated goat 
anti-mouse IgG (HSP60) and swine anti-rabbit IgG (TLR2 and TLR4)
(DakoCytomation, Denmark) incubation, followed by a steptavidin
amplification reagent. Double staining visualization was finalized by fast red
(TLR2 and TLR4) and fast blue (HSP60) application.
Vascular smooth muscle cell proliferation 
VSMCs were seeded on glass coverslips (5000 cells/cm2) in 24-well plates and
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synchronized for 24 hours in F-12K medium, supplemented with 2% fetal calf
serum. In some experiments, VSMCs were incubated in different concentrations
of recombinant human HSP60 for 48 hours. In others, TLR2 or TLR4 antibodies
were added 30 minutes before exposure to HSP60. After 48 hours, cells were
washed in PBS, fixed in formaldehyde, and permeabilized in MP-40 for 20
minutes. Nonspecific binding sites were blocked with 2% BSA. To determine
VSMC proliferation, VSMCs were incubated with a mouse anti-human 
Ki67 antibody, followed by FITC-conjugated rabbit anti-mouse IgG
(DakoCytomation, Denmark). Visualization was done by means of confocal
fluorescence microscopy.  
For each experimental group and control group, total nuclei and Ki67
positive nuclei were counted by an observer blinded to the specimen group. In
total 4 experiments were done.
HEK cell proliferation
HEK cells, either transfected with TLR2 or TLR4/MD2 or with the empty vector
pcDNA (control), were seeded at a density of 4x106 cells/flask and incubated
with human HSP60 (1 or 20mg/ml) in DMEM/1% FCS for 48 hours. The
attached cells were harvested by trypsinization and cell number was
determined using a hemocytometer. 
Statistics
Data were expressed as mean ± SE. Student’s t test was used for the comparison
between the different groups. Differences were considered significant at P<0.05. 
Results
Co-localization of HSP60 and Toll-like receptors
We determined the expression of HSP60, TLR2, and TLR4 in neointimal lesions
from failed arteriovenous fistulas. Since we hypothesized a direct stimulating role
for human HSP60 in TLR2 and TLR4 mediated VSMC proliferation, we verified
whether these mediators co-localized in (partially) occluded vascular segments.
Immunohistochemical double-staining revealed a clear co-localization of TLR4
and HSP60 in venous neointimal lesions (Fig. 1A). TLR2 also co-localized with
HSP60, albeit to a lesser extent than TLR4 (Fig. 1B). In contrast, control saphenous
veins were deficient in TLRs and HSP60 (Fig. 1C and 1D). Negative controls,
where the primary antibody was substituted with a non-immune IgG from the
same species, confirmed specificity of the staining procedure (data not shown). 
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Figure 1. 
Immunohistochemical analysis of TLR2, TLR4 and HSP60 proteins. A, doublestaining for TLR4 (red)
and HSP60 (blue) in AVF neointimal lesion. Arrows indicate double-positive cells for TLR4 and
HSP60 (detail). B, doublestaining for TLR2 (red) and HSP60 (blue). Arrows indicate double-positive
cells for TLR2 and HSP60 (detail). C and D, Doublestaining for TLR2 or TLR4 (red) respectively and
HSP60 (blue) in control venous segments. Arrows indicate diffuse TLR2 and TLR4 staining in medial
cells. Hardly any positive HSP60 immunoreactivity could be detected. Bar=100μm.
Human HSP60 induces VSMC proliferation
To investigate the mitogenic effect of human HSP60 on quiescent smooth
muscle cells, we determined the percentage of Ki67 positive nuclei on a glass
coverslip containing a total of ~5000 cells after 48 hours of human HSP60
stimulation (Fig. 2A). Exposure to HSP60 for 48 hours resulted in a
concentration dependent increase in VSMC proliferation , with a maximum
observed at 20 μg/ml recombinant HSP60 (Fig. 2A). 
Induction of VSMC proliferation by human HSP60 is TLR2 and TLR 4 dependent
To confirm that the effect of human HSP60 is mediated by stimulation of TLR2
or TLR4, we investigated the effect of TLR antibodies. We pre-incubated
quiescent VSMCs for 30 minutes with either TLR2 or TLR4 antibodies, before
adding 10 μg/ml HSP60 for 48 h. Both TLR2 and TLR4 antibodies attenuated
the stimulatory effect of HSP60 in a concentration dependent way (Fig. 2B).   
HSP60 induces proliferation of HEK cells transfected with human TLR2 or
TLR4/MD-2 
HEK cells naturally lack TLR2 and TLR4, and genetic complementation with
these receptors renders HEK cells responsive to their respective ligands. To
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Figure 2. 
Human heat shock protein 60 stimulates VSMC proliferation in a concentration and TLR2/4
dependent way. A, VSMCs were exposed to increasing concentrations of recombinant human
HSP60 for 48 hours (n=4 experiments). In the control group, VSMCs were exposed to medium
containing 2% FCS. Pretreatment of the HSP60 preparations (20mg/ml, 20 min. 100oC)
attenuated VSMC proliferation to control levels.  B, anti-TLR2 and anti-TLR4 antibodies attenuated
the mitogenic effect of 10 μg/ml HSP60 (control group) in a concentration dependent way (n=4
experiments). *P<0.05 and #P<0.01, significantly different from control.
further scrutinize the importance of TLR2 and TLR4 in mitogenic signaling, we
compared the proliferative response of transfected and control HEK cells to
human HSP60. When TLR2- and TLR4/MD2-expressing HEK cells were
exposed to HSP60 (20mg/ml, 48h), total cell number increased 2.2 and 2.1-
fold, respectively (p<0.05 for both), when compared to control HEK cells,
thereby providing further evidence that HSP60 invigorates cell proliferation by
stimulating TLR2 as well as TLR4. Low (1 μg/ml) HSP60 concentration did not
significantly induce HEK-TLR2 or HEK-TLR4/MD-2 cell proliferation.
Human HSP60-induced VSMC proliferation is not due to LPS contamination 
Bacterial products like lipopolysaccharide (LPS) are known to activate cells
through TLR4 or even TLR27, 20. Since Gao and Tsan21 recently demonstrated
that contamination of commercially available recombinant human HSP60
preparations with LPS could be responsible for cellular activation, it was crucial
to exclude that LPS contamination was responsible for the effects observed in
the present study. Therefore, we determined the LPS content of the HSP60
preparations used in our experiments by LAL assay and found that the amount
of LPS was <0.2 pg/ml (below detection limits) This supports the concept that
indeed HSP60, and not LPS, is responsible for the observed increase in cell
proliferation which is in agreement with earlier data by Gao et al, who found
comparable levels of endotoxin in their preparations, and demonstrated that
these levels had no significant effect on cellular activity21.
To further exclude LPS involvement in our study, we pre-treated our
HSP60 preparations for 20 minutes, 100°C22 prior to the 48h incubation
period. Heat pretreatment completely abolished the mitogenic effect of our
preparation. Therefore, we are confident that the observed effects can be
attributed to HSP60 stimulation and not to LPS contamination.
Discussion
In the present study we demonstrated that human HSP60 is a potent inducer of
VSMC proliferation. Human HSP60 significantly augmented VSMC proliferation
above control levels in a dose dependent fashion. Moreover, we showed that
human HSP60 uses TLR2 as well as TLR4 to cause its mitogenic effect on
VSMCs. Selective inhibition of TLR2 and 4 signaling attenuated HSP60-induced
proliferation in a dose dependent way. Besides, HSP60 significantly stimulated
the proliferation of HEK cells, expressing either TLR2 or TLR4/MD2, over
control levels. Since we also demonstrated co-localization of HSP60 and TLR4
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and to a lesser extent TLR2 in venous neointimal lesions, a causative and
interacting role for aforementioned proteins in cardiovascular disease seems
even more likely. These results reinforce the data on HSP60, TLR2 and TLR4
involvement in cardiovascular disease.
Inappropriate flow conditions effectively induce HSPs3, 10, which have
been suspected to provoke autoimmune reactions resulting in atherogenesis2
and unbalanced neointimal formation23-24. Other studies showed HSP60
induction in monocytes/macrophages, SMCs, and endothelial cells in human
atherosclerotic lesions. First prove of human HSP detection in diseased vascular
tissue reverts to the early 90’s when Kleindienst et al25 demonstrated HSP60
expression in atherosclerotic lesions. However, data relating HSPs to vein graft
disease are scarce. To our knowledge only one report demonstrated enhanced
HSP60 and HSP70 expression in saphenous veins exposed to a hypoxic
milieu26. In the present paper, we demonstrate a marked up-regulation of
endogenous HSP60 in failed arteriovenous fistulas. While positive
immunostaining for HSP60 was almost absent in control veins, HSP60
immunoreactivity was prominently present in failed fistulas. As failure of such
fistulas is mainly due to intemperate VSMC proliferation, we hypothesized that
endogenous, ‘self’ HSP60 may contribute to VSMC proliferation.
Data from our in vitro experiments support this hypothesis. When VSMC
were exposed to human HSP60, a dose dependent increase in Ki67 positive
cells was observed, indicating that HSP60 indeed stimulates VSMC
proliferation. Already 1 μg/ml HSP60 was sufficient to induce VSMC
proliferation above quiescent levels. Nonetheless, it remains to be questioned
whether such concentrations are physiologically relevant. Interestingly, Pockley
et al10 observed soluble HSP60 levels >3 μg/ml in patients with borderline
hypertension. As might be assumed that HSP60 levels within the vascular wall
are even higher, a true physiological role for endogenous HSP60 is highly
likely.
Evidence is mounting that TLR2 and TLR4 act as receptors for HSP60,
thereby mediating its proliferating effects possibly by NF-kB activation and
mitogen-activated protein kinase pathways with subsequent production of
various proliferation-stimulating cytokines13. In particular, the recently
suggested molecular link between TLR and the TGF-β super family may be of
interest 27. Furthermore, the presence of TLR has been demonstrated not only
on antigen presenting cells, such as macrophages and dendritic cells, but also
on endothelial cells, adventitial fibroblasts and SMCs. Recently, a direct link
between TLR4 and vascular remodeling has been demonstrated.  In mouse
models it has been shown that adventitial TLR4 activation by LPS augments the
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development of atherosclerotic lesions and stimulates neointima formation28.
Moreover, flow-induced arterial remodeling, which is characterized by a
significant increase in the arterial expression of HSP60 and TLR4 mRNA, is
markedly diminished in mice lacking a functional TLR4 receptor, thereby
strengthening the idea that both TLR4 and locally produced endogenous HSP60
contribute to the development of vascular disorders. In line with this is our
observation that HSP60 and TLR4 antigens are far more present in the diseased
vascular wall and are co-localized in venous neointima, which further
nourishes the hypothesis of a HSP60/TLR4 interaction in the development
and/or the progression of various cardiovascular diseases. 
In contrast to TLR4, TLR2 has been paid less attention with respect to
cardiovascular disease. Nevertheless, TLR2 is also expressed on human
endothelial cells and monocyte derived macrophages. Also, in atherosclerotic
plaques the expression of TLR2 has been demonstrated13. And although initially
described as a receptor for peptidoglycans, HSP60 has also been described as
a putative ligand for this receptor resulting in the activation of the Toll-like
receptor/interleukin-1 receptor signaling pathway in innate immune cells29.
When we examined the presence of TLR2 in failed arteriovenous fistulas, we
found a marked up-regulation of TLR2 antigen expression in the venous
neointima, although the up-regulation was not as pronounced as was found for
the TLR4 receptor. Furthermore, HSP60 expression was found to co-localize
also with TLR2 and in vitro experiments revealed that TLR2 receptor blockade
was as effective as or even more effective at high concentrations in preventing
VSMC proliferation than blockade of the TLR4 receptor. To stretch the role of
TLR2 and 4 even further, we determined the effect of HSP60 on HEK cells
transfected with human TLR2 or TLR4/MD-2. As expected, wild-type HEK cells
which naturally lack TLRs were non-responsive to HSP60 while genetic
complemented HEK cells showed a more than 2-fold increase in cell number
after 48 hours of HSP60 exposure. As we found no difference between TLR2
and TLR4 transfected HEK cells, the seemingly more important role for TLR2 in
HSP60 signaling as suggested in our blocking experiments in VSMC might be
caused by an aspecific effect of the TLR2 receptor antibody at higher
concentrations. Overall, these results demonstrate that both TLR2 and TLR4
might contribute significantly in HSP60 induced cell proliferation. Intriguingly,
recent in vitro data suggest that stimulation of both TLR2 and 4 results in
secretion of matrix metalloproteinases (MMP) by activated monocytes and mast
cells30,31. Also, increased transcription of MMP-1 and MMP-3 by cervical
smooth muscle following TLR4 stimulation has been demonstrated32. Since
MMP production and activation are critical steps in vascular remodeling as they
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facilitate SMC proliferation and migration, TLR mediated stimulation of MMP
activation may also significantly contribute to vascular remodeling and failure
of arteriovenous fistulas.
As mentioned before, others already demonstrated a direct stimulatory
effect of HSP60 on VSMCs via TLR4 signaling12. However, in this study
Chlamydia pneumoniae HSP60 was used. Our results suggest that not only
HSP60, derived from bacterial sources, but also human HSP60 stimulates
VSMC proliferation, which raises the theory of an autocrine mechanism in
venous neointimal formation. As altered hemodynamic conditions, such as at
bifurcations or in venous bypass grafts, give rise to a marked up-regulation in
HSP60 production, this may have serious consequences for the ultimate clinical
outcome. Along the same line Hirono et al6 demonstrated that human HSP60,
over-expressed in SMC, resulted in a small but significant increase in
proliferation. However, in contrast to our and Sasu’s data no effect was found
on proliferation levels when chlamydial HSP60 was added exogenously. The
reason for this discrepancy remains to be established.
There is one important issue that needs to be discussed. Previously, it has
been suggested that the earlier reported activation of macrophages and SMCs
by recombinant human HSP60 was due to LPS contamination21. However, we
believe that contamination is not responsible for the noticed induction of VSMC
proliferation in our study. First, we used commercially obtained, highly purified
human HSP60, proven to have low endotoxin levels21. In agreement, we
determined endotoxin levels in our HSP60 preparation by LAL assay, and could
not find any significant amounts of endotoxin (detection level of the assay 0.2
pg/ml). Also, we preheated our preparations containing the highest HSP60
concentration before use. It is well established that such treatment eliminates
the HSP60 but leaves LPS intact22. However, no effect on proliferation was
observed when this pre-heated preparation was added to the VSMC culture.
Therefore, we are convinced that our results truly represent HSP60-induced cell
proliferation and not a concomitant effect of LPS contamination.
In summary, to our knowledge this is the first report demonstrating a
stimulating effect of exogenously applied human ‘self’ HSP60 on VSMC
proliferation. Hereby our results surpass the common notion of infection related
vascular pathologies, and imply a possible HSP60-induced autocrine process.
Furthermore, as HSP60 and both TLR receptor types were markedly up-regulated
in the neointima of failed arteriovenous fistulas, this indicates a true physiological
role for such autocrine mechanisms. Moreover, these data implicate TLR2 and 4
as possible targets for intervention to limit unfavorable neointimal formation.
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N-acetylcysteine attenuates
hyperoxia induced venous 
smooth muscle cell proliferation
and neointima formation 
in a rat venous graft model
Abstract 
Introduction. Neointima formation is an important cause of venous bypass graft
failure. The significance of exposure of a vein to supra-physiological oxygen
levels following implantation in the arterial circulation has not been addressed
in the pathophysiology of smooth muscle cell proliferation that is characteristic
of intimal hyperplasia. The aim of this study was to investigate whether
hyperoxia triggers venous smooth muscle cell proliferation. Furthermore, we
studied the therapeutic potential of the antioxidant N-acetylcysteine to
attenuate the detrimental effects of hyperoxia on smooth muscle cell
proliferation and neointima formation in venous grafts.
Methods and Results. To investigate whether hyperoxia triggers venous smooth
muscle cell (VSMC) proliferation, isolated human VSMCs were cultured under
hyperoxic (70% O2) or normoxic (21% O2) conditions for 72 hours. Secretion
of the mitogenic inflammatory cytokines IL-6 and IL-8 was 5-fold and 20-fold
higher, respectively, in hyperoxic compared with normoxic VSMCs. 
Subsequently, normoxic VSMCs were incubated with medium derived from
hyperoxic VSMCs. This cytokine-rich medium induced proliferation of
normoxic quiescent VSMCs as indicated by a 9-fold increase in the number of
Ki-67 positive VSMC nuclei after a 72-h incubation period. Treatment of VSMCs
with the antioxidant N-acetylcysteine (NAC) prevented hyperoxia-induced
cytokine production and VSMC proliferation. The therapeutic potential of NAC
was further investigated in vivo using a rat venous graft model. Systemic
administration of NAC significantly reduced smooth muscle cell proliferation at
7 days and attenuated neointima formation at 3 weeks in venous grafts.
Conclusions. Vein grafts endure hyperoxia following implantation in the arterial
circulation. This potential stressor has as yet been disregarded in the
pathogenesis of vein graft disease. The present study shows that hyperoxia
induces VSMC proliferation. This effect is associated with a hyperoxia-induced
increase in the secretion of mitogenic inflammatory cytokines by VSMCs. The
antioxidant NAC prevents hyperoxia-induced cytokine production and VSMC
proliferation, and attenuates neointima formation. The identification of
hyperoxia as a novel element in the multifactorial process of neointima
formation opens a window of opportunity by targeting oxidant-antioxidant
mismatch to prevent venous bypass graft failure.  
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Introduction
Implantation of autologous saphenous vein segments in the arterial circulation
has been the treatment of choice for many years to bypass peripheral and
coronary arterial obstructions. However, vein graft stenosis and occlusion due
to neointima formation is a major problem resulting in unsatisfactory patency
levels1. Intimal hyperplasia is characterized by medial smooth muscle cell
proliferation and migration into the intima, increased extracellular matrix
deposition, and formation of a thick neointima. Arterial bypass conduits exhibit
superior patency rates as opposed to saphenous vein conduits. This disparity
has been attributed to differences in the structural, cellular and molecular
composition of arterial and venous walls, resulting in altered adaptation to
arterial hemodynamics2,3, and different responses to atherogenic and mitogenic
stimuli in arterial and venous grafts4. Recently, oxidative stress has also been
related to differences in patency between vascular grafts5. 
Oxidative stress, defined as an imbalance between reactive oxygen
species (ROS) and endogenous antioxidants in the vascular tissue, is suggested
to play an important role in the pathogenesis of cardiovascular diseases like
atherosclerosis, hypertension and heart failure5-7. ROS, including OH, H2O2,
and O2
-, are generated by virtually all types of vascular cells8. Excessive levels
of these radicals have been shown to induce endothelial dysfunction with
subsequent impairment of anticoagulant and anti-inflammatory properties and
smooth muscle cell activation9. 
Venous grafts exhibit higher oxidative stress than arterial grafts10. Thus far
it is assumed that oxidative stress in venous grafts relates to vascular trauma, i.e.
surgical injury and hemodynamic stress11-13. However, an obvious source of
oxidative stress in venous grafts may be the exposure of the implanted venous
segment to the high-oxygen environment of the arterial circulation. Detrimental
effects of a hyperoxic environment have been well appreciated in pulmonary
artery remodelling14,15 and in cardiac tissue injury following cardiac
reoxygenation16. Surprisingly, the effect of relative hyperoxia on venous smooth
muscle cells (VSMCs) and its role in neointima formation in venous grafts have
not been investigated. 
The vasculature has adequate antioxidant reserves to cope with the
production of ROS under physiological conditions. However, when ROS
production is excessive, such as during prolonged stress, basal antioxidant
mechanisms may be overwhelmed by ROS. Pioneering epidemiological
research has suggested beneficial effects of antioxidant vitamin intake on
cardiovascular risk profile17. Successive studies have attempted to boost
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antioxidant levels in the vasculature to preserve vascular function and reduce
restenosis in experimental animal models. N-acetylcysteine (NAC), a thiol,
which for one is a strong scavenger of oxygen-free radicals, has been widely
employed to counterbalance oxidative stress in vascular cells. It proved
successful in preventing arterial restenosis by several proposed mechanisms
like NF-KB inhibition18, reduction in platelet activity19 and interference with
PDGF β-receptor signaling20. Thus far, no studies have been performed on the
potency of NAC to interfere with neointima formation in venous bypass grafts.
We hypothesize that hyperoxia adds to oxidative stress, proinflammatory
changes and subsequent neointima formation in venous bypass grafts and that
treatment with NAC attenuates these processes. Therefore, in the present study
the effects of hyperoxia on VSMC cytokine production and proliferation were
investigated in vitro. Furthermore, we focussed on the therapeutic potential of
NAC to restore the oxidant-antioxidant mismatch and decrease neointima
formation in venous grafts in vivo. 
Methods
In vitro
Cell culture
Human venous smooth muscle cells (VSMCs) were obtained from ATCC
(Manassas, USA), and cultured in F-12K medium (Kaighn’s Modification of Ham’s
F-12 Medium), supplemented with 0.1 mg/mL heparin, 0.03 mg/mL endothelial
cell growth supplement, and 10% fetal calf serum. Cells were grown under
normoxic (21% O2-5% CO2) conditions. Passages 4-6 were used for experiments.
Cytokine analysis  
Cells were seeded at a density of 5 x 105 cells/mL in 24-well cell culture plates and
synchronized for 24 h in F-12K medium supplemented with 2% fetal calf serum
under normoxic (21% O2-5% CO2) conditions. Subsequently, quiescent VSMCs
were placed in an incubator under hyperoxic (70% O2-5% CO2) or normoxic
(21% O2-5% CO2) conditions. Po2 and Pco2 in the medium were measured in
preliminary experiments with a blood gas analyzer. Mean Po2 was 714 mmHg and
173 mmHg under hyperoxic and normoxic conditions, respectively. The Pco2 and
pH values of the culture medium were similar under normoxic and hyperoxic
conditions. Medium and cells were collected following 12, 24, 48 and 72 h of
incubation under either hyperoxic or normoxic conditions. Viability of the cells
was determined by trypan blue staining. Conditioned medium was immediately
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analyzed for cytokine concentration. The human inflammation Cytometric Bead
Array kit (BD Biosciences, NJ, USA) was used to quantitatively measure cytokine
(IL-1ß , IL-6, IL-8, IL-10, TNF-α, IL-12p70) expression levels in VSMC culture
media. Fifty microlitres of conditioned medium were used and the assay was
performed according to the manufacturer’s instructions and analyzed on the
FACSCalibur® flow cytometer (BD Biosciences, NJ, USA).
Cell proliferation assay
VSMCs were seeded on glass coverslips (5000 cells/cm2) in 24-well plates and
synchronized for 24 h in F-12K medium, supplemented with 2% fetal calf
serum under normoxic conditions. Again, conditioned medium from VSMCs
was collected following incubation for 12, 24, 48 and 72 h under either
hyperoxic or normoxic conditions and transferred immediately to quiescent
normoxic VSMCs, which were subsequently placed in an incubator under
normoxic conditions for 48 h. After 48 h, cells were washed in PBS, fixed in
formaldehyde, and permeabilized in NP-40 for 20 minutes. Nonspecific
binding sites were blocked with 2% BSA. VSMCs were incubated with mouse
anti-human Ki-67 (DakoCytomation, Denmark) antibody, followed by a
secondary antibody (goat anti-mouse; DakoCytomation). Finally, VSMCs were
incubated with horseradish peroxidase-coupled streptavidin (Vector
Laboratories, CA, USA), followed by immunodetection using DAB as a
substrate, and counterstaining with haematoxylin. For each experimental group
and control group, total nuclei and Ki-67 positive nuclei were counted by an
observer blinded to the specimen group. Proliferation index was calculated as
the amount of positive cells divided by total cell count.
Effect of NAC on hyperoxia-induced cytokine production and VSMC proliferation
It has been suggested that intracellular changes induced by oxidative stress
might be attenuated by the antioxidant agent NAC. To examine the effect of
NAC on hyperoxia-induced cytokine production in VSMCs, NAC (Sigma-Aldich
Sweden AB, Stockholm, Sweden) was added to F-12K medium to a final
concentration of 2 mmol/L. VSMCs were incubated with NAC-enriched medium
under hyperoxic conditions (70% O2-5% CO2). At 12, 24, 48, and 72 h after
exposure to hyperoxia, 2 mL of conditioned medium was removed and
transferred immediately onto quiescent normoxic VSMCs which were further
incubated under normoxic conditions. After 48 h a proliferation assay was
performed on these cells as described above. An additional 2 mL of
conditioned medium was used for cytokine quantification by means of a
Cytometric Bead Array kit as described above.
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In vivo
Animals
Male inbred specific pathogen free (SPF) Lewis rats were obtained from the
Department of Experimental Animal service of the University of Maastricht, the
Netherlands. Experiments were performed in animals aged 12 weeks weighing
300-400 gram. Housing and care of the animals, and all the procedures used in
this study were approved by the Ethical Committee for the Use of Experimental
Animals of the institution, and were in accordance with the Guide for the Care
and the Use of Laboratory Animals, published by the US National Institute of
Health (NIH Publication No. 85-23, revised 1985). Rats were fed standard rat
chow and tap water at libitum. All surgical procedures were performed under
general anesthesia and using sterile techniques. 
Rat venous graft model and drug treatment protocol
Autologous epigastric vein-to-common femoral artery interposition grafts
were placed in rats as previously described21. Briefly, each animal was
anesthetized with an intraperitoneal injection of pentobarbital sodium (60
mg/kg). An 8-mm segment of the relaxed ipsilateral epigastric vein was
carefully harvested, gently irrigated with heparinized saline solution (100
U/mL), and placed as reverse interposition graft into a segmental 3-mm
defect of the common femoral artery with 8 to 10 interrupted sutures of 11-
0 nylon (Ethicon). The entire procedure was carried out with standard
microsurgical techniques. The total ischemic time was kept to less than 30
min. Patency was verified by visual inspection. In total 28 rats were
recovered from anaesthesia. Animals were randomized to either NAC
treatment (n=14) or saline control group (n=14). The respective groups
received either 2 mL NAC solution (150 mg/kg bodyweight NAC in NaCl
0.9%) or 2 mL saline once a day via oral gavage. Drug treatment was started
at 2 days prior to surgery and continued until sacrifice. Rats were sacrificed
7 days (NAC n=7, control n=7) or 3 weeks (NAC n=7, control n=7) after vein
graft surgery. To determine proliferation rates in vein graft segments at 7 days
of surgery, bromodeoxyuridine (BrdU, 30 mg/kg ip) was administered at 18
h and 12 h prior to euthanasia. Rats were anaesthetized, the chest and
abdominal cavities were opened, and a catheter was inserted into the apex
of the heart. Blood vessels were initially flushed with physiological salt
solution and then perfusion fixed with 3.7% formaldehyde in phosphate-
buffered saline, pH 7.4, at physiological pressure (100 mm Hg). Vein grafts
were removed, fixed overnight in the same fixative, routinely processed and
paraffin embedded. 
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Histomorphometric analysis
Cross-sections (4 μm) were taken for morphometrical analysis at 200-μm intervals
and mounted on glass slides for haematoxylin–eosin (HE) and elastin (Lawson)
staining. VSMCs were detected by a monoclonal anti-smooth muscle actin antibody
(DakoCytomatic, Denmark), endothelial cells were identified by a monoclonal rat
endothelial cell antibody (RECA-1, Abcam). Medial thickness, neointimal area (area
between the internal elastic lamina and endothelium) and percentage of stenosis
(area within the endothelium divided by the area within the internal elastic 
lamina) were determined on two mid-graft sections, using a computer-assisted
morphometry system (analySIS®, Soft Imaging System, Munster, Germany). 
BrdU immunoreactivity was detected in vein graft segments by a specific
monoclonal anti-BrdU antibody (1/500 dilution, DakoCytomatic, Denmark). After
DNA denaturation with 2N HCl and enzymatic pretreatment with pepsin, BrdU
immunohistochemistry was performed with biotinylated goat anti-mouse IgG
(DakoCytomation, Denmark) and the ABC-AP kit with Fast Red and counterstaining
with haematoxylin for quantification. Presence of VSMCs in neointimal lesions 
was determined by a monoclonal anti-α smooth muscle actin antibody
(DakoCytomatic, Denmark).
Statistics
Data are expressed as mean ± SE. Differences between the experimental and
control groups for cytokine analysis and comparisons between groups for
morphometric analyses were made using the Mann-Whitney U test. Differences
were considered significant at a value of P < .05.
Results
Hyperoxia induces cytokine production by VSMCs
Viability of cells was >95% at 0 h, and >80% at 72 h of hyperoxia treatment as
determined by trypan blue staining. VSMCs exposed to 70% O2 showed a time-
dependent increase in the production of IL-8 and IL-6 as compared with VSMCs
incubated at 21% O2 (Figure 1). In contrast, IL-10 levels in medium were on
average below the detection limit of the assay (3.3 pg/mL). No significant
increase from baseline concentration of IL-1β, Il-12p70 or TNF-α was found in
both hyperoxic and normoxic cells (Table 1). 
Medium from hyperoxic VSMCs induces proliferation of normoxic VSMCs
Quiescent VSMCs incubated under normoxic conditions were exposed for 48 h
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Figure 1.
Culturing of venous smooth muscle cells under hyperoxic conditions induces increased secretion of
mitogenic cytokines. Both IL-8 (A) and IL-6 (B) levels in the culture medium, as determined by
Cytometric Beads Array assay, significantly increased during exposure to 70% O2 (hyperoxia, black
bars) as compared with exposure to 21% O2 (control, grey bars). Concomitant administration of
the antioxidant NAC (hyperoxia/NAC, white bars) completely abolished hyperoxia-induced
cytokine expression. Data represent the mean ± SE of four experiments. * P < .01 versus control
Table 1. Effects of hyperoxia and NAC on cytokine secretion by VSMCs
IL-1β IL-6 IL-8 IL-10 IL-12p70 TNF-α
0 h control ND 30 ± 12 186 ± 80 ND ND ND
12 h control 35 ± 10.6 315 ± 163 323 ± 49 ND 3.1 ± 1.2 2.7 ± 1.0
12 h O2 - NAC 34 ± 16.4 309 ± 134 874 ± 200 ND 4.2 ± 2.1 2.4 ± 0.9
12 h O2 + NAC 31 ± 9.6 330 ± 106 1078 ± 632 ND 3.7 ± 2.1 2.2 ± 1.0
24 h control 30 ± 9.5 536 ± 119 485 ± 234 ND 5.0 ± 2.8 3.4 ± 1.6
24 h O2 - NAC 22 ± 10.6 780 ± 100 2560 ± 351 * ND 7.3 ± 4.3 2.4 ± 1.1
24 h O2 + NAC 31 ± 8.7 380 ± 151 209 ± 67 ND 5.5 ± 2.7 1.9 ± 0.5
48 h control 27 ± 12.1 485 ± 49 631 ± 336 ND 3.3 ± 2.3 2.3 ± 0.8
48 h O2 - NAC 26 ± 12.5 1503 ± 120 * 5470 ± 1509 † ND 5.9 ± 4.1 2.5 ± 0.9
48 h O2 + NAC 26 ± 11.3 340 ± 149 210 ± 90 ND 3.8 ± 2.4 2.9 ± 1.3
72 h control 32 ± 9.9 546 ± 94 360 ± 37 ND 3.6 ± 2.4 2.3 ± 0.2
72 h O2 - NAC 34 ± 11.3 2729 ± 223 * 7614 ± 731 * ND 9.3 ± 3.9 3.4 ± 1.7
72 h O2 + NAC 32 ± 9.3 187 ± 164 315 ± 121 ND 6.5 ± 2.9 2.1 ± 0.8
Values represent mean ± SE of four experiments and all values are expressed in pg/mL. 
Control, exposure to 21% O2
O2 - NAC, exposure to 70% O2 without NAC 
O2 + NAC, exposure to 70% O2 with NAC
* P < .01, † P < .05 versus control; ND: not detectable
to medium retrieved from hyperoxia-exposed VSMCs. Direct cell counting revealed
a significant increase in the number of Ki-67 positive VSMC nuclei incubated with
conditioned medium as compared with VSMCs incubated with control medium
(Figure 2). Incubation with conditioned medium obtained after 24, 48 and 72 h of
hyperoxia induced a 4, 6, and 9-fold increase of Ki-67 positive cells, respectively. 
NAC prevents hyperoxia-induced cytokine production and VSMC proliferation
To determine the effects of NAC treatment on proinflammatory cytokine secretion
from VSMCs, 2 mmol/L NAC was added to the culture medium and quiescent
VSMCs were subsequently exposed to hyperoxia. Treatment with NAC prevented
the increase in IL-8 and IL-6 levels after 24, 48 and 72 h of hyperoxia (Figure 1),
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Figure 2. 
Medium from hyperoxic VSMCs induces proliferation of quiescent normoxic VSMCs, which is
prevented by NAC. Proliferation indices in normoxic VSMCs after 48-h incubation with conditioned
medium retrieved from VSMCs after 24-72 h of hyperoxia induced a significant increase in the
number of Ki-67 positive cells (red bars, * P < .01 versus incubation with control medium).
Administration of NAC to quiescent VSMCs reduced the proliferative effect of medium from
hyperoxic VSMCs (yellow bars, # P < .05 versus medium from hyperoxic VSMCs, ie versus red bars).
The proliferative response of quiescent VSMCs was completely abolished by conditioned medium
from hyperoxic NAC-treated VSMCs (blue bars, † P < .05 versus medium from hyperoxic VSMCs
that had not been treated with NAC, ie versus yellow bars). Data are expressed as mean ± SE of
four experiments.
but did not affect the secretion of other measured cytokines (Table 1). These data
show that exposure of VSMCs to hyperoxia leads to secretion of mitogenic
cytokines Il-6 and Il-8 and proliferation of quiescent VSMCs. 
Since NAC attenuated the secretion of IL-6 and IL-8, we next determined the
mitogenic effects of conditioned medium retrieved from VSMCs which received
NAC throughout exposure to hyperoxia. Proliferation rates of normoxic VSMCs
after 48-h incubation with conditioned medium from hyperoxic NAC-treated
VSMCs were significantly reduced to quiescent normoxic levels as compared to
incubation with medium from hyperoxic VSMCs that had not been treated with
NAC (Figure 2). These data indicate that medium retrieved from hyperoxia-exposed
and NAC-treated VSMCs lost its mitogenic potential. 
Since NAC has been suggested to cause growth-arrest of SMCs22, we also
determined the direct effects of NAC on VSMCs stimulated by conditioned
medium. Quiescent VSMCs were incubated with conditioned medium retrieved
from hyperoxia-exposed VSMCs with the addition of 2 mmol/L NAC. Proliferation
rates were determined after 48-h culture under normoxic conditions. NAC
treatment of quiescent normoxic VSMCs reduced the proliferative response of
these cells to medium from hyperoxia-exposed VSMCs, supporting a direct
inhibitory effect of NAC on VSMC proliferation. However, this direct anti-
proliferative effect of NAC on normoxic VSMCs was significantly smaller than the
aforementioned inhibitory effect of NAC treatment of hyperoxic VSMCs on
subsequent normoxic VSMC proliferation (Figure 2).
NAC inhibits neointima formation in rat venous grafts
At 7 days of surgery, one vein graft in the control group was occluded by
thrombosis and excluded from analysis. None of the vein grafts in the NAC-treated
group exhibited thrombosis. Anti-BrdU staining was performed in all remaining
vein graft segments (control n=6, NAC n=7; Figure 3). A scale between 1 (few) and
4 (abundant) was used to obtain a semi-quantitative index of the number of
proliferating cells in the media and neointima of experimental vein grafts.
Proliferation scores were significantly lower in the NAC-treated compared with the
control group (1.5 ± 0.2 versus 3.1 ± 0.2, P = .004). The majority of cells in the
vein segments were qualified as VSMCs, as determined by anti-α smooth muscle
actin staining.
At 3 weeks of surgery, thrombosis was seen in 1 segment from the control
group and 1 from the treatment group. Morphologic measurements were
performed on the remaining vein graft segments (control n=6, NAC n=6).
Neointimal area in the NAC-treated group was significantly reduced compared
with the control group (Figure 4a, Figure 5). Furthermore, the stenosis rate in
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grafted veins in the NAC-treated group was 6-fold lower compared with the
control group (Figure 4c). In contrast, media thickness did not differ between
treatment and control groups (Figure 4b). Taken together, these results demonstrate
that NAC inhibits neointima formation in experimental vein grafts, through
reduction of VSMC proliferation. 
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Figure 3. 
Systemic treatment with NAC reduces VSMC proliferation in rat venous grafts. VSMC proliferation
is significantly lower in vein grafts of NAC-treated (B; 150 mg/kg/d orally; n=7) compared with
control rats (A; n=6) at 7 days of surgery, as demonstrated by BrdU immunohistochemistry
(arrowheads). Scale bars represent 100 μm.
Figure 4. 
Systemic treatment with NAC inhibits neointima formation in rat vein grafts. A. Neointimal area in
venous grafts at 3 weeks of surgery was significantly reduced in NAC-treated (150 mg/kg/d orally;
n= 6) compared with control (n=6) rats. B. Medial thickness of grafted veins was not significantly
different between NAC-treated and control groups. C. Percentage stenosis was significantly lower
in the NAC-treated compared with the control group. Data are expressed as mean ± SE. # P < .05,
* P < .01 versus control.
Discussion
Neointima formation is a complex process of multifactorial origin. What does
actually happen when a vein is implanted into the arterial circulation? Two
major changes in the venous environment occur. First, the vein is exposed to
the high blood pressure of the arterial tree. Second, the vein is exposed to the
oxygen-rich blood of the arterial circulation. The influence of mechanical
factors on the integrity of the venous wall is subject of extensive research. For
example, cyclic high pressure stretching has been shown to trigger a cascade of
molecular events in endothelial and smooth muscle cells which have been
linked to the development of thrombosis, neointima formation and
atherosclerosis23. Surprisingly, no attention has been paid to the effects of
hyperoxia on the vein wall. This was the subject of the current study. We
demonstrate that hyperoxia initiates a proinflammatory response in VSMCs
resulting in VSMC proliferation. Treatment with the antioxidant NAC inhibits
this process, and prevents neointima formation and vein graft stenosis. 
The potential effects of hyperoxia on the vein wall were investigated in
smooth muscle cells, not in endothelial cells, since vein grafts are rapidly
denuded from their endothelium by surgical manipulation and hemodynamic
stress. We found that exposure of isolated human VSMCs to 70% O2 induced a
marked increase in IL-6 and IL-8 secretion, whereas the levels of IL-1β, TNF-α,
and IL-10 remained unaffected. Induction of IL-6 and IL-8 secretion under
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Figure 5. 
Abundant neointima formation (*) is present in a vein graft segment from a control animal at 3
weeks of surgery (A). Treatment with NAC prevents neointima formation (B), as shown by Lawson
elastin staining. Scale bars represent 100 μm.
hyperoxic conditions has previously been shown in macrophages24,25.
Furthermore, the only study thus far that examined effects of hyperoxia on
vascular wall cells found an increase in IL-8 mRNA levels in human umbilical
vein endothelial cells26. Reports on the expression of other inflammatory
cytokines, including IL-1β, are conflicting, since both increased and decreased
expression have been reported in response to hyperoxia24,26,27. To investigate
the mitogenic potential of hyperoxia-induced secretion of IL-6 and IL-8, we
transferred medium retrieved from hyperoxic VSMCs onto quiescent VSMCs
and noticed significant proliferation. These findings are in line with previous
studies which identified the mitogenic properties of proinflammatory cytokines
IL-6 and IL-8 in smooth muscle cells28,29,30.
In contrast to the cytokine-mediated proliferative effect of hyperoxia,
direct exposure of VSMCs to hyperoxia did not lead to proliferation (data not
shown). Congruent with these findings, previous studies demonstrated that in
vitro hyperoxia induces growth arrest in the S-phase of the cell cycle31. In vivo,
however, hyperoxia has been shown to induce smooth muscle cell proliferation
in pulmonary arteries in a rat model32. This discrepancy between in vitro and in
vivo effects of hyperoxia on smooth muscle cell proliferation may relate to the
position of the smooth muscle cell within the vascular wall. Arterial partial
oxygen pressure decreases from 90 mmHg to 35 mmHg within a 1 mm
distance in the vessel wall as measured from the lumen33. We suggest that
although high luminal oxygen concentration might lead to growth arrest in the
first cell layers, paracrine stimulation by high levels of IL-6 and IL-8 secreted by
the hyperoxic cells may well induce smooth muscle cell proliferation in the
medial cell layers.
Our data suggest that oxidative stress is implied in the origin of vein graft
disease. Hyperoxia is a well-known potent inducer of ROS. An imbalance
between the production and degradation of ROS induces oxidative damage.
Previous studies demonstrated that the antioxidant NAC may reduce arterial
stenosis in experimental models of balloon-induced arterial injury18,19,34.
Therefore, we examined the therapeutic potential of NAC to prevent vein graft
stenosis. We show that NAC prevented the hyperoxia-induced increase in
secretion of the mitogenic cytokines IL-6 and IL-8 by VSMCs. Consequently,
treatment with NAC abolished the proliferative response of VSMCs to medium
retrieved from hyperoxic VSMCs in vitro. The potential of NAC to inhibit VSCM
proliferation was confirmed in vivo. We found that NAC strongly attenuated
neointima formation and vein graft stenosis in a rat venous bypass graft model
by reducing VSMC proliferation. These findings provide experimental evidence
for a promising novel role for NAC. The antioxidant properties of NAC have
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been shown to be of benefit in many clinical conditions, including sepsis,
respiratoy failure, hepatic failure, and prevention of radiographic contrast
nephropathy35. Further clinical studies are required before it can be
recommended for the routine management of venous bypass grafts and,
potentially, arteriovenous hemodialysis fistulas.     
In summary, these data indicate that the antioxidant N-acetylcysteine can
prevent hyperoxia-induced venous smooth muscle cell proliferation. Our study
presents a novel concept in the pathophysiology of neointima formation and
provides a potential therapy for venous graft stenosis.      
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Detection of cell-cycle regulators
in failed arteriovenous fistulas 
for hemodialysis
Abstract 
Background. Renal failure (RF) patients rely on arteriovenous fistulas (AVFs) for
hemodialysis vascular access. Intimal hyperplastic stenoses result in failure of
AVFs and frequent interventions are required to maintain vascular access. The
extent of intimal hyperplasia (IH) depends on the interplay between cyclins and
cyclin dependent kinases (e.g. cdk2), positively regulating cell cycle
progression. Cdk activity is negatively modulated by the interaction with cdk
inhibitory proteins, such as p21Waf1 and p27Kip1. Little is known about the
expression of these proteins in the development of IH in AVFs. 
Methods and Results. p21Waf1, p27Kip1, cdk2, and PCNA immunoreactivity was
determined in 18 failed AVFs from 16 RF patients and 10 non-diseased vessels
(5 arteries and 5 veins). The percentage p21Waf1 positive cells was significantly
lower in AVFs (3 ± 1%), compared to normal veins and arteries (62 ± 4% and
63 ± 4%, respectively; p < 0.001). Cdk2 positive cells were significantly higher
in AVFs (40.7 ± 3.7%) than in normal veins and arteries (2 ± 1% and 0 ± 0%,
respectively; p < 0.001). Although no difference in p27Kip1 immunoreactivity
was found between AVFs (37 ± 17%) and veins (23 ± 8%; p = 0.208), it was
lower in healthy arteries (17 ± 11%; p = 0.037).
Conclusions. These data suggest that in failed AVFs p21Waf1, but not p27Kip1, is
related to IH. This is the first report to show involvement of cell cycle regulators
in AVF-related human intimal hyperplasia.
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Introduction
Intimal hyperplastic stenoses in surgically created arteriovenous fistulas (AVFs)
for hemodialysis remain a serious problem in maintaining vascular access.
One-year primary patency rates vary from 53-88% for autogenous radio-
cephalic wrist fistulas to 37-70% when prosthetic grafts are used1. Pathological
proliferation and migration of vascular smooth muscle cells (VSMC) resulting in
intimal thickening is the main cause of graft stenosis and occlusion within the
first year after AVF construction2,3. In normal vascular tissue, quiescent VSMCs
are found in the G0 phase of the cell cycle and VSMCs proliferate at a low rate.
However, on stimulation VSMCs can exit their quiescent state and progress
through the G1 and G1/S transition of the cell cycle
4,5.
Cell cycle progression is positively regulated by the formation of
complexes comprised of cyclin-dependent kinases (CDK) and their activating
subunits, the cyclins. Cdk activity is, in turn, negatively modulated by the
interaction with cdk inhibitory proteins (CKIs), resulting in cell cycle arrest6.
Progression through the first gap (G1) phase requires both cyclin D-cdk4/6
(early G1) and cyclin E-cdk2 (late G1)
5. Specific CKIs (p21Waf1 and p27Kip1) are
capable of blocking cell cycle progression by inhibiting cyclin E-associated cdk
complexes7.
Expression of these CDKs and CKIs in arterial balloon injury models and
the role of these cell cycle proteins in VSMC proliferation have been
investigated in cultured bovine, porcine, and human endothelial and smooth
muscle cells as well as in human atherosclerotic lesions and normal porcine
arteries8,9. However, it is not known how the expression of these cell cycle
regulators relate to venous intimal hyperplasia as a result of hemodynamic
forces which are relevant in AVFs. Therefore, we investigated the expression of
p21Waf1, p27Kip1, cdk2, and Proliferating Cell Nuclear Antigen (PCNA) in AVFs
and non-diseased vascular tissue.
Material and methods
Tissue Specimens
Eighteen specimens of stenotic AVFs were obtained from 16 patients (8 men
and 8 women; age: 59.8 ± 3.4 year) undergoing AVF revision at the surgical
department of the University Hospital Maastricht. Hypertension was diagnosed
in 12 patients (75%) and only one patient presented with non-insulin
dependent diabetes. The diagnosis of stenosis was based on generally accepted
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Duplex ultrasound criteria and confirmed by angiography10. The study was
approved by the joint Medical Ethical Committee of the Maastricht University
and the University Hospital Maastricht and the patients were included after
written informed consent.
AVF revision was performed 27 months (range 1-80 months) after primary
access creation. In 14 of 18 AVFs vascular access was created through a
prosthetic brachial-anticubital forearm loop access, while in the 4 other cases,
an autogenous radial-cephalic direct wrist fistula was constructed. During
revision, the stenotic lesions were obtained and fixed in 10% formalin for 4
hours, followed by 18 hours in 70% ethanol, and paraffin-embedded for
immunocytochemistry. Sections (4 μm thick) were stained with haematoxylin
and eosin, and immunostained with p21Waf1, p27Kip1, cdk2, and PCNA
antibodies.
Five normal arteries were obtained during obduction from patients who died
of non-cardiovascular cause. Remnants of vein grafts used for arterial
revascularization were obtained (n = 5). Both non-diseased arteries and veins were
formalin fixed, paraffin-embedded and stained with afore mentioned antibodies.
Immunocytochemistry
Serial sections of the tissues were incubated with the following primary
antibodies: a mouse monoclonal anti-human p21Waf1 antibody, 1:50 dilution
(NeoMarkers, Inc. Fremont, CA, USA); a mouse monoclonal anti-human
p27Kip1 antibody, 1:50 dilution (NeoMarkers); a mouse monoclonal anti-human
cdk2 antibody, 1:50 dilution (NeoMarkers); and a mouse monoclonal anti-
human PCNA antibody, 1:30 dilution (NeoMarkers). Sections (4 μm thick) were
deparaffinized in three changes of xylene, and rehydrated in 90%, 70%, and
50% ethanol. Slides were boiled in citrate buffer for 20 min, and incubated in
2% BSA/PBS/tween for 20 minutes to block aspecific binding activity. Primary
antibodies were diluted in TBS and applied to the slides for 60 minutes at room
temperature. After 3 washes with TBS for 5 minutes, a biotinylated horse anti-
mouse secondary antibody (1:400 dilution, Dako) was applied for 30 minutes
at room temperature, followed by a steptavidin amplification reagent (Dako) for
30 minutes at room temperature. Finally, Fast Red was used for 10 minutes at
room temperature, yielding a red reaction product. Visualization of all nuclei in
the tissue sections was realized with a haematoxylin counterstain.
Total nuclei, and positive nuclei were counted in the (neo-)intima of the
different vascular segments by means of a microscope-based video image
analysing system (Analysis®, Soft Imaging System, Münster, Germany). Four
random high-power fields of each specimen were analysed.
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Statistical analysis
Data management and statistical analysis were performed with the SPSS 10.0
package for Windows (SPSS, Chicago, Ill., USA). Data are presented as mean
values and standard errors of the mean (SEM). Mean percentages in the patient
group and control tissues were compared by means of ANOVA with Bonferroni
correction. Simple linear regression analysis was performed to correlate patient
characteristics (such as sex, age, and present cardiovascular risk factors ) and
graft survival to cell cycle regulating proteins.
Results
Cell cycle regulators in AVFs and non-diseased vascular tissue
All vascular segments were stained with p21Waf1, p27Kip1, cdk2, and PCNA
antibodies and total nucleic, and immunoreactive nucleic count was determined
in 4 random high-power fields. The average number of nuclei counted was
4,416 in AVFs, 1,363 in non-diseased veins, and 1,262 in non-diseased arteries.
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Figure 1. 
Immunocytochemical staining of healthy and intimal hyperplastic vascular segments. Shown are
Fast Red-stained nuclei in normal veins: (A) p21Waf1, (B) p27Kip1, (C) cdk2, and (D) PCNA; normal
arteries: (E) p21Waf1, (F) p27Kip1, (G) cdk2, and (H) PCNA; AVFs: (I) p21Waf1, (J) p27Kip1, (K) cdk2,
and (L) PCNA expression. Bar, 100 μm.
Whereas p21Waf1 was clearly expressed to a greater extent in non-diseased veins
and arteries, cdk2 and PCNA positive cells were more frequently detected in
failed AVFs (figure 1). p27Kip1 immunoreactivity was observed both in non-
diseased and stenotic tissue (figure 1). Figure 2 shows the percentage of positively
stained cells for p21Waf1, p27Kip1, cdk2, and PCNA, respectively. The percentage
p21Waf1 positive cells was significantly lower in AVFs (3 ± 1%) compared to non-
diseased veins and arteries (62 ± 9% and 63 ± 8%, resp.; p < 0.001). In contrast,
cdk2 and PCNA positive cells were abundantly present in AVFs (41 ± 16% and
37 ± 15%, respectively) while immunopositive cells were almost absent in non-
diseased veins (0 ± 0%, and 0 ± 0%, resp.; p < 0.001) and arteries (2 ± 2%, and
1 ± 0.4%, resp.; p < 0.001). p27Kip1 immunoreactivity was lower in arteries
compared to failed AVFs (17 ± 11% and 37 ± 14%, resp.; p = 0.037).
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Figure 2. 
Expression of p21Waf1, p27Kip1, cdk2, and PCNA in arteriovenous fistulas for hemodialysis, normal
veins and arteries. Data are presented as mean percentages ± standard error of the means. * = p
< 0.001 compared to expression in AVFs; # = p < 0.05 compared to expression in AVFs.
However, between veins and AVFs no difference was found in p27Kip1
immunoreactivity (23 ± 8%; p = 0.208). Correction for the variables age, sex,
and cardiovascular risk factors had no influence on the level of significance. No
relation was found between the different cell cycle regulating proteins and
patient history of former AVFs or the number of revisions.
Discussion
Although cell cycle regulator expression in normal, balloon-injured, and
atherosclerotic vascular tissue has been described8,9, this has not yet been
reported in human intimal hyperplastic lesions.
Normal human arteries and veins are mainly characterized by the
presence of quiescent VSMCs in the media. This is supported by our finding that
p21Waf1 and p27Kip1 are abundantly expressed in non-diseased human arteries
and veins. In contrast, cdk2 expression was absent in veins and minimally
expressed in arteries. Considering the afore mentioned characteristics of the cell
cycle machinery, these results agree with earlier studies, showing a correlation
between CKI (p21Waf1, p27Kip1) expression and VSMC quiescence8,11,12.
Intimal hyperplasia (IH), ensuing stenosis is characterized by an increased
VSMC proliferation and migration from the media to the intima. p27kip1 and
p21waf1 expression might be expected to be reduced in IH. However, in the
present study p27kip1 does not seem to play a significant role. In contrast,
p21waf1 expression was considerably lower in stenotic AVFs. These findings
collaborate the notion that p21Waf1 is a negative regulator of VSMC proliferation
and thus IH in AVFs8,11,12. The prevailing theory of p21Waf1 negatively
modulating cdk2 expression is reflected by our finding that cdk2 is profusely
expressed in intimal hyperplastic lesions.
Wei et al have shown a temporally and spatially coordinated expression of
cdk2, cyclins E and A, and PCNA in a rat balloon-injury model13. Unfortunately,
we were not able to examine cell cycle protein expression through time due to
the retrospective nature of the study. Further investigations in time-dependent
cell cycle protein expression are needed to elucidate cell cycle protein function
in intimal hyperplasia and eventually providing a site for intervention.
Recently, there has been a growing interest in the role of therapeutical
means in preventing restenosis after vascular reconstruction. For example,
rapamycin has been shown to inhibit VSMC proliferation and migration in vitro
and arterial intimal thickening after balloon injury in vivo by a stabilizing effect
on p27Kip1.14 In addition, Tranilast has been found to inhibit proliferation and
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migration of VSMCs and collagen synthesis15 by induction of p21Waf1 and p53,
preventing restenosis after PTCA16. In the present paper, we demonstrated
dramatic reduction of p21Waf1 levels in occluded AVFs. It might be anticipated
that an imposed stabilisation or even up-regulation of p21Waf1 might inhibit
VSMC proliferation, thereby preventing AVF stenosis.
The altered expression of several cell cycle proteins in failed AVFs
contributes to intimal hyperplasia. Since the cell cycle machinery is accessible
for therapeutic intervention, it is our opinion that it might be an attractive target
to prevent intimal hyperplasia in AVFs. Large randomised placebo-controlled
intervention studies are required to prove noteworthy reduction in intimal
hyperplasia after AVF construction.
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The new immunosuppressive 
agent FK778 attenuates 
neointima formation in an
experimental bypass model
Abstract 
Introduction. Neointimal formation, characterized by proliferation and
migration of smooth muscle cells, plays a central role in the pathogenesis of
vein graft disease. In this whole process, intemperate cell cycle progression is
an unfavourable factor and might be a promising target for intervention. We
examined the potency of the immunosuppressive agent FK778 to interfere with
smooth muscle cell cycle progression and inhibition of vein graft neointimal
formation.
Material and methods. Quiescent venous smooth muscle cells were incubated
for 48 hours with 10% FCS and different concentrations of FK778. Cell
proliferation was measured by means of Ki-67 immunostaining. Uridine was
added to reverse FK778 induced pyrimidine synthesis blockade. A rat venous
bypass model was used to evaluate the effect of 15 mg/kg FK778 on neointimal
area, percentages of stenosis and medial thickness. Sixteen male inbred specific
pathogen free Lewis rats were used to perform femoral artery interposition graft
surgery.
Results. FK778 inhibited venous SMC proliferation in a dose dependent
manner, while this effect was reversed by addition of uridine. Furthermore,
FK778 significantly reduced neointimal formation and percentage of stenosis in
experimental vein grafts.
Conclusions. FK778 is a potent inhibitor of venous smooth muscle cell
proliferation and neointimal formation in experimental vein grafts. Thus, FK778
might provide a new pharmacological therapy to interfere with unfavourable
neointimal formation in vein grafts.
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Introduction
Although minimal invasive procedures like subintimal recanalisation, balloon
dilatation and arterial stenting have been introduced to overcome peripheral
atherosclerotic obstructive disease, venous bypass grafting often remains the
treatment of choice. However, venous graft patency is hampered by
hemodynamically-induced attrition, and subsequent failure of bypass grafts.
Over recent years, many, mainly pharmacological therapies have been
introduced to increase venous graft patency rates. For example, early graft
failure has been reduced by anti-platelet agents1 2, and late atherosclerosis
related graft failure prevented by aggressive lipid lowering therapies3. Although
these strategies had some success, neointimal formation, as a result of
intemperate smooth muscle cell (SMC) proliferation, still contributes
significantly to venous bypass failure. Several mechanisms implicated in
unfavorable intimal thickening have been targeted by means of
pharmacological agents like MMP inhibitors4 and angiotensin-converting
enzyme (ACE) inhibitors5, but also genetic manipulation of distinct mechanisms
has proven efficacy6. Although promising, theses types of therapy remained
largely experimental and as yet are not proven feasible in the clinical setting.
Furthermore, due to the multifactorial nature of intimal thickening, inhibition of
an individual stimulus is unlikely to be effective and advocates targeting of
downstream events.
Since SMC proliferation may be seen as the hallmark of neointimal
formation, and the final common pathway of SMC proliferation relies on cell
cycle progression, this pathway emerged as a prosperous target for intervention.
Accordingly, direct inhibition of SMC proliferation by blockage of the cell cycle
has recently been investigated and generated several drugs found to prevent (re-)
stenosis. Especially local drug release has been successful, which is
emphasized by excellent patency results of sirolimus-coated stents in the
prevention of secondary coronary artery and saphenous vein graft stenosis after
percutaneous transluminal angioplasty (PTA)7 8. Alternatively, oral administration
of anti-proliferative drugs may also be used to prevent excessive intimal
thickening, which is underscored by reduced in-stent restenosis after oral
immunosuppressive therapy9 10. However, conflicting data question the
potency of oral sirolimus to prevent restenosis in coronary stents11 and adverse
effects like dyslipidemia hamper the therapy’s efficacy12. Therefore, there is a
need to discover drugs with anti-proliferative potency and minimal side effects. 
The synthetic malononitrilamide (MNA) FK778 is a new immunosuppressive
agent structurally similar to A77 1726, the active metabolite of leflunomide,
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which proved to be beneficial in several autoimmune and inflammatory
diseases. Also, it has recently been shown that FK778 exerts antiproliferative
effects similar to leflunomide. In contrast, FK778 lacks the adverse aspects of
leflunomide (half life of 15-18 days) thus emerging as an interesting candidate
for in vivo intervention of SMC proliferation and vein graft neointima formation. 
The present study was designed to examine the inhibitory potential of
FK778 on venous SMC proliferation and neointima formation in venous bypass
grafts in an experimental animal model.
Methods
Reagents 
FK778 (2-cyano-3-oxo-N-[4-(trifluoromethyl)phenyl]-6-heptanoic acid amide) was
a generous gift from Fujisawa Healthcare Inc. (Osaka, Japan). Uridine (Sigma, St
Louis, MO, USA) was prepared as a 10 mM stock solution in cell culture medium.
Monoclonal anti-Ki67 antibody was obtained from DakoCytomation, Denmark. For
oral administration, FK778 powder was mixed with 1% carboxymethylcellulose in
water until a final concentration of 5 mg/ml was obtained. 
Cell culture
Human venous smooth muscle cells were obtained from ATCC (Manassas,
USA), and cultured in F-12K medium (Kaighn’s Modification of Ham’s F-12
Medium), supplemented with 0.1 mg/ml heparin, 0.03 mg/ml endothelial cell
growth supplement (ECGS), and 10% fetal calf serum (FCS). Passages 4-6 were
used for experiments.
Subsequently SMCs were seeded in 24-wells plate (5000 cells/well) and
synchronized for 24 hours in F-12K medium, supplemented with 2% fetal calf
serum. Then the incubation medium was replaced by growth factor supplemented
F-12K medium containing different concentrations of FK778 (1-30μM) and 10%
FCS. In additional experiments, uridine was also added to the incubation medium
at a concentration of 1 mM. After 48 hours, cells were washed in PBS, fixed in
formaldehyde, and permeabilized in NP-40 for 20 minutes. To determine SMC
proliferation, SMCs were incubated with a mouse anti-human Ki67 antibody,
followed by FITC-conjugated rabbit anti-mouse IgG (DakoCytomation,
Denmark). Visualization was done by means of fluorescence microscopy.
Animal conditions
Sixteen male inbred specific pathogen free (SPF) Lewis (LEW) rats were
106
Chapter 6
obtained from the Department of Experimental Animal service of the University
of Maastricht, the Netherlands. Experiments were carried out on animals aged
12 weeks weighing 300-400 gram. Housing and care of the animals, and all the
procedures used in this study were approved by the Ethical Committee for the
Use of Experimental Animals of the institution, and conformed to the Guide for
the Care and the Use of Laboratory Animals, published by the US National
Institute of Health (NIH Publication No. 85-23, revised 1996). Rats were fed
standard rat chow and tap water at libitum. All surgical procedures were
performed under general anesthesia and using sterile techniques. 
Experimental design
Autologous epigastric vein-to-common femoral artery interposition grafts were
placed in 16 rats by the use of a method similar to that described earlier by
Hoch et al.13. Briefly, each animal was anesthetized with an intraperitoneal
(i.p.) injection of pentobarbital sodium (60mg/kg). An ~8mm segment of the
relaxed ipsilateral epigastric vein was carefully harvested, gently irrigated with
heparinized saline solution (100 U/ml), and placed as reverse interposition graft
into a segmental 3mm defect of the common femoral artery with 8 to 10
interrupted sutures of 11-0 nylon (Ethicon). The entire procedure was carried
out with standard microsurgical techniques. The total ischemic time was kept to
less than 30min. Patency was verified by visual inspection. 
Eight animals received daily an oral dose of 15 mg/kg body weight starting
1 day prior to the operation until the day of sacrifice. Eight control rats received
3ml of 1% carboxymethylcellulose solution only.
Three weeks after surgery, rats were anaesthetised, the chest and
abdominal cavities were opened, and a catheter was inserted into the apex of
the heart. Vessels were initially flushed with physiological salt solution and then
perfusion fixed with 3.7% formaldehyde in phosphate-buffered saline, pH 7.4,
at physiological pressure (100 mmHg). Vein grafts were removed and fixed
overnight in the same fixative. The fixed vein grafts were routinely processed
and paraffin embedded. Cross-sections (4 μm) were taken for morphometrical
analysis at 200-μm intervals and mounted on glass slides for
haematoxylin–eosin (HE) and Lawson staining. Medial thickness, neointimal
area and percentage of stenosis were determined by using a computer-assisted
morphometry system (analySIS®, Soft Imaging System, GmbH). 
Statistics     
Data were expressed as mean ± SE. Student’s t test was used for the comparison
between the different cell culture groups. Comparisons between groups for
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morphometric analyses were made using the two-sample Wilcoxon rank-sum
(Mann-Whitney) test. Differences were considered significant at P<0.05. 
Results 
Serum induced venous SMC proliferation is inhibited by FK778 
The anti-proliferative potency of FK778 was studied on serum stimulated
venous smooth muscle cells. Ki-67 immunoreactive cells were counted 48
hours following stimulation with 10% FCS in the presence of increasing
concentrations of FK778. FK778 inhibited the proliferation of venous SMCs in
a dose dependent manner (Figure 1). Reduction of SMC proliferation was
already significant at a concentration of 3μM and maximum inhibition was
obtained at 30μM. Although it has been suggested that FK778 may exert
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Figure 1. 
FK778 dose-dependently inhibits Ki-67 immunoreactivity in 10% FCS stimulated smooth muscle
cells, while uridine (1mM) reverses the inhibitory effect of FK778 on smooth muscle cell
proliferation. The values are plotted as a percentage of proliferating smooth muscle cells to the
total amount of cells. Data points are expressed as mean ± SEM of four different cultures tested.
*P<0.01, significantly different from control. 
cytotoxic effects when used in high (>100μM) concentrations14, in our hands
no signs of cell death were seen, even at the highest concentration of FK778
used, indicated by the absence of a positive trypan blue staining. To
demonstrate that the observed inhibition of proliferation was due to FK778,
uridine was added to the culture medium. For all FK778 concentrations used,
the addition of 1mM uridine returned proliferation rates to control values
(Figure 1).   
FK778 attenuates neointimal formation in experimental vein grafts
No apparent clinical signs of illness were observed in any of the animals during
the follow-up period. Starting body weight ranged from 300 g to 400 g; at the
end of the experiments animal weight ranged from 350 g to 450 g. Body weight
did not differ between the experimental group and the control group. (data not
shown). 
The mean medial thickness of native veins was 10±2μm. Three weeks after
bypass grafting, media thickness increased significantly in all veins irrespective
whether rats were FK778 or sham treated. Nevertheless, no differences were
observed between both groups (sham: 36.0±2.3μm versus FK778 42.3±4.2μm,
fig 2A). Also, neointimal thickening was observed in all graft but marked
109
FK778 attenuates venous neointima formation
Figure 2. 
A-C: FK778 (15 mg/kg) treated animals versus controls. A. medial thickness of grafted veins does
not differ between experimental and control groups. B. Neointimal area is significantly reduced in
the FK778 treated group compared to the control group. C. Percentage of stenosis is significantly
lower in the FK778 treated group. Data points are expressed as mean ± SEM. *P<0.01,
significantly different from control. #P<0.01, significant different from native vein.
differences were observed between control and FK778-treated rats (figure 3).
Morphometric analyses revealed a significant reduction in the neointimal area
following FK778 treatment compared to the control group (5852±934μm2
versus 14747.5±2750μm2) (Figure 2B). Furthermore, the stenosis rate in grafted
veins in the FK778 treated group was approximately 6-times lower compared to
the control group (8.8±3.6% versus 52.6±11.1%, p<0.01, fig 2C, data are
expressed as mean percentages of the lumen size to the area inside the internal
elastic lamina).
Discussion
In the present study, we demonstrated that FK778 is a potent inhibitor of venous
SMC proliferation. Moreover, oral treatment with FK778 attenuated neointimal
formation in a rat epigastric-to-common femoral artery interposition graft
model. 
FK778 has been developed as an alternative for leflunomide, of which its
active metabolite A77 1726 shares structural similarities with FK778 and
proved beneficial in the treatment of various diseases. Initially, leflunomide was
successfully applied in the treatment of rheumatoid arthritis, but was also used
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Figure 3.
Three weeks after vein grafting. Representative images after Lawson staining of a control vein
graft (A) and FK778 treated vein graft (B). Arrowheads represent the lamina elastica interna. The
media-aventitia border is indicated by small arrows. The large arrow indicates the native vein in situ
adjacent to the grafted vein, which shows normal intimal and medial thickness. Notice the marked
increase in medial thickness of both control and FK778 treated vein grafts compared to the native
vein. Moreover, medial thickness is similar in both vein grafts. Scale bar: 100 μm.
to treat autoimmune diseases and graft rejection15. Successive research showed
that leflunomide is also effective in attenuating rat aortic smooth muscle
proliferation16. This raised the question whether leflunomide could be used as
an anti-proliferative drug to prevent vein graft failure. However, due to the long
half-life and gastrointestinal toxicity of leflunomide17, applicability in clinical
practice is hampered. In contrast, FK778 provides a more favorable pharmacologic
profile in that it shares the same therapeutic efficacy without the extended half-
life of leflunomide. 
This triggered us to examine if FK778 could be applied to restrain venous
SMC proliferation and prevent vein graft stenosis. Indeed, we were able to
demonstrate that FK778 has the potency to inhibit serum dependent human
venous SMC proliferation in a dose dependent manner. Earlier, others have
attributed the anti-proliferative effect of malononitrilamides to inhibition of the
de novo pyrimidine biosynthesis16 18. As proliferative responses to 10% FCS
could be restored completely by the addition of uridine, this suggests that SMC
proliferation likewise depends on de novo synthesis of pyrimidine. Some cell
types with high turn over rates, like the gastrointestinal lining cells, have
previously been shown to be rather insensitive to the anti-proliferative effects of
FK778, probably because they use salvage pathways for pyrimidine
ribonucleotide synthesis19. Our results now suggest that proliferating vascular
smooth muscle cells, as can be found in vein grafts or balloon-injured arterial
segments, seem in short supply of pyrimidine, and are therefore obliged to
synthesize pyrimidine de novo during the initial stages of neointimal formation.
This suggests that proliferating smooth muscle cells might be potential targets
for therapeutic interventions with FK778. 
To test this and to verify our in vitro data, we used an experimental venous
bypass graft model. Here, we demonstrate for the first time that FK778
effectively reduces neointimal formation in a rat epigastric vein-to-common
femoral artery interposition graft model of intimal hyperplasia13. A similar
vasculoprotective potency of FK778 to reduce neointimal formation, most
likely independent of its immunosuppressive effects, has recently been shown
in rat aorta injury models 20.  In agreement with these data, our results similarly
showed a significant decrease in neointimal area after oral treatment with 15
mg/kg FK778. Next to its anti-proliferative effect, it has also been suggested that
FK778 directly reduces the up-regulation of endothelial adhesion molecules
and attenuates lymphocyte-endothelium interaction in a transplantation model 21.
Although we did not scrutinize this possibility, this effect may have also aided
in reducing the neointimal formation found in our model. 
In addition to the neointimal area, we determined the percentage of stenosis in
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vein grafts. In our opinion, this parameter is of clinical significance, because it
better resembles the functionality of the vein graft than the area of neointimal
formation. Our data show that FK778 treatment not only prevented the
hyperplastic response but also reduced the percentage of stenosis in the graft.
Nevertheless, maturation of the graft was not impaired as the increase in medial
thickness was comparable between groups. Interestingly, this increase in medial
thickness does not seem to result from an increase in cell number, but appears
to be dependent on extracellular matrix deposition, as revealed by HE staining
(data not shown).
Several animal studies examined the characteristics of FK778 and its
efficacy to prevent allograft rejection, and determined the nature and incidence
of adverse side effects. Depending on the different mechanisms studied,
variable drug doses were used, ranging from 5mg/kg/day to 25mg/kg/day. Even
with the highest concentrations used no deaths have been reported so far,
although some adverse effects were seen in animal groups treated with 25
mg/kg/day. However, at efficacious doses hardly any complications have been
reported. Accordingly, in the present study the effective dose of 15 mg/kg/day
did not result in any deaths among the treated animals, nor was any discomfort
noticed. Additionally, and in agreement with the present and other animal
studies, recent clinical trials evaluated the safety of FK778 and its predecessor
leflunomide and found few adverse events like diarrhea, increased liver
functions and anemia22. In contrast, FK778 may even decrease total cholesterol
and LDL-cholesterol levels, thus establishing a favorable cardiovascular risk
profile22. Obviously, it is rather enticing to integrate this suggested attractive
characteristic into the already favorable outcome prospect of FK778 in vein
graft disease as we present in the current study. Taken together, it is of interest
to commence clinical studies to investigate the potency of FK778 to interfere
with vein graft neointimal formation and arterial restenosis after PTA.
Yet, some limitations of the present study should also be noted. It still
needs to be clarified which dose of FK778 is most efficacious without causing
adverse side effects. In contrast to long term periods as suggested for the
treatment of diseases like rheumatoid arthritis, a relatively short treatment
period might suffice for the prevention of intimal hyperplasia in vein graft as we
observed a marked reduction in both neointimal formation as well as
percentage of stenosis after only a 3 week treatment period. Furthermore, since
it has been suggested that the starting time of treatment is more important than
the duration of treatment23,24, we initiated the treatment period already at 1 day
prior to surgery. Nevertheless, it needs further clarification which treatment
strategy leads to the most favorable outcome in preventing graft failure.
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Furthermore, the present study did not make it indisputable that the inhibition
of neointimal formation was merely the result of anti-proliferative effects of
FK778. The family of MNAs exhibit anti-inflammatory effects as well, which
might very well add to the control of neointimal formation. It has been shown
that MNAs inhibit the expression of pro-inflammatory cytokines and adhesion
molecules, thereby attenuating injury response and the process of neointimal
formation25. 
With the introduction of immunosuppressive drugs with anti-proliferative
potential a new era has begun in the treatment of cardiovascular diseases.
However, obviously developed to target other disease patterns, the balance
between positive and adverse effects should continually be evaluated for every
field of application. Evidently, the present study shows that the immunosuppressive
agent FK778 has great potential to inhibit venous SMC proliferation in vitro and
prevent venous neointima formation in vivo, without causing adverse side
effects. The latter has been vastly supported by recent patient studies reporting
few complications and even a possible favorable cardiovascular risk profile,
which solicits confirmation of our findings in a clinical setting.      
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Failure of venous bypass grafts and subsequent intervention weighs heavily on
today’s patient’s quality of life and healthcare capacity. Despite extensive
research into the mechanisms leading to graft failure and the development of
multiple pharmacological agents and surgical techniques to prevent
disproportionate remodeling, currently no effective strategy has emerged. The
main goal of the present thesis was to expose unknown culprits that serve the
development of venous intimal thickening and further, judge the potential of
pharmacological agents to inhibit the harmful effects of these mediators.
Furthermore, we tried to discover a prognostic method to determine the risk of
future vein graft failure, by examining morphologic aspects of the autologous
vein at the time of implantation.  
Inflammation, smooth muscle cell proliferation and vein graft neointima formation
Numerous studies have been conducted to discover mechanisms and pathways
involved in venous intimal thickening and several emerged in recent years.
Accordingly, the process of neointimal formation in vein grafts should be
considered multifactorial. Therefore, it would be utopian to assume that
treatments targeting an individual mechanism or pathway would be feasible or
even adequate to prevent excessive intimal thickening. Nevertheless, discovery
of unknown mediators might increase our knowledge regarding neointimal
formation in vein grafts and lead us in the right way to further reduce the
number of bypass failures.  
The majority of previous research addressing the etiology of neointimal
formation has been done in arterial injury models. In line with ample evidence
demonstrating a prominent role for inflammation-dependent mechanisms in
arterial neointima formation, recently a relation between inflammation and the
venous wall response to injury has been presented1,2. Thus, pro-inflammatory
cytokines and growth factors appear to be an important link between the
altered hemodynamic milieu and ultimate SMC proliferation/migration in vein
grafts. Endothelial cells sense hemodynamic alterations and are known to react
by secreting several vasoprotective and pro-inflammatory agents, that in turn
activate SMCs to migrate and proliferate. Furthermore, hemodynamic stress
induces up-regulation of monocyte chemoattractant protein (MCP)-1, which is
closely followed by monocyte/macrophage infiltration and neointimal
formation3,4. In addition, cell-mediated damage of vein grafts induces up-
regulation of adhesion molecules, which increases the affinity for circulating
inflammatory cells and platelets5. On activation, these cell types both secrete
pro-inflammatory cytokines with high mitogenic potential for SMCs. In
experimental animal models it has previously been shown that
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monocytes/macrophages and T-cells infiltrate vein grafts after implantation6. In
chapter 2 we confirmed these findings when we demonstrated significant
higher levels of macrophages and T-cells in venous neointimal lesions,
compared to control veins. Moreover, we immunohistochemically evaluated
small sections from veins predestined for venous bypass graft surgery, and
correlated this with clinical outcome one year post-surgery. Interestingly, we
observed a significant larger number of macrophages and T-cells in veins which
failed in the following year. Predisposing factors for vein graft failure have been
recognized earlier, as general cardiovascular risk factors like smoking,
dyslipidemia, hypertension and diabetes all showed to hamper long term
patency. However, there was no instrument available that could indicate which
vein grafts were prone to fail in the future. With our results we were the first to
present a possible prognostic method to predict future venous bypass failure.
Also, our findings underscore the inflammatory nature of venous intimal
thickening. Furthermore, immune-mediated mechanisms known to be involved
in the pathogenesis of atherosclerosis7 now are stronger implicated in venous
intimal hyperplasia. 
T-lymphocytes, like macrophages produce many different cytokines that
stimulate growth, differentiation and chemotaxis. A primary role of immune
reactions in venous intimal hyperplasia was underscored by Cherian et al who
found colocalization of T-cells and dendritic cells in intimal hyperplastic
lesions, indicating an antigen presenting relationship8. Candidate antigens that
may lead to a humoral and/or cellular immune response include modified
lipoproteins, intracellular antigens exposed through cytolysis or necrosis and
antigens of infectious organisms such as cytomegalovirus, and Chlamydia
pneumoniae. Heat shock proteins (HSP) assemble another very interesting
group of antigens. HSPs have been implicated in the maintenance of the
inflammatory/immunologic response observed in atherosclerotic lesions, and
the expression of human HSP60 correlates positively with the severity of
atherosclerotic lesions9. HSPs or “stress proteins” comprise a family of proteins
demonstrating highly homologous sequences between various species, from
bacteria to humans. This high degree of amino acid sequence homology
between human and microbial HSP60 (antigen mimicry) has been the
foundation for the autoimmune hypothesis in atherosclerotic disease7.
Specifically, infection of vascular cells with Chlamydia pneumoniae for
instance causes an increase in both Chlamydial and human HSP60, and cross-
reaction with both HSPs might thus lead to an (auto) immune response to
vascular cells10. However, several entities other than infection have been
shown to induce HSP production by vascular cells, like oxidative stress,
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cytokine stimulation, and mechanical stress11. Of interest is the substantial
production of HSP60 by endothelial cells in response to hemodynamic stress12. 
HSP60 has also been suggested to incorporate inflammatory qualities,
epitomized by HSP60 induced triggering of signal transduction via the pro-
inflammatory MAPK pathway13. Furthermore, HSP60 has been shown to
induce the production of pro-inflammatory cytokines such as tumor necrosis
factor (TNF)-α, interleukin (IL)-1, IL-6, and IL-1214, and in turn, is up-regulated
by pro-inflammatory cytokines itself. Thus, potential paracrine and autocrine
mechanisms by which endogenous HSP60 might be involved in the process of
neointima formation are abundant. In chapter 3 we found that autogenous
HSP60 features yet another cytokine function in that it directly stimulates
human venous SMC proliferation, and that this mitogenic effect could be
inhibited by blocking Toll like receptors (TLR) 2 and 4, which are the suggested
receptors for HSP60. TLRs however are known to recognize lipopolysaccharide
(LPS) which induces cellular responses similar to those suggested for HSP60.
Therefore, we were very meticulous to exclude the danger of contamination
with LPS in our preparations used to examine HSP60 induced SMC
proliferation. Both Limulus amebocyte lysate (LAL) assay and heat inactivation
of our preparations were used, and convinced us that the mitogenic effect of
HSP60 was not due to contamination with LPS. In order to make a more
practical interpretation of our findings we studied venous neointima lesions and
healthy veins by immunohistochemistry. Evidently, both TLR2 and TLR4 co-
localized with HSP60 in venous neointima lesions, and visibly to a larger extent
then in healthy veins. Although HSP60 is originally a mitochondrial protein that
can be translocated into the cytoplasm under stress conditions, it is well
understood that HSPs can be released in the extracellular compartment
independent of cell death, but in response to a number of stressful conditions15.
Furthermore, circulating HSP60 reside in healthy individuals and elevated
HSP60 levels relate to pathological conditions, like hypertension and
atherosclerosis16,17,18. Because of the high levels and different types of stress,
particularly in vein grafts just after implantation, it is conceivable that local
extracellular HSP60 reaches high levels and thus contributes significantly to
SMC proliferation. Whether autogenous HSP60 indeed plays a significant role
in neointima formation in vivo should be further investigated in animal models.
In chapter 4 we presented an additional mechanism that as yet has not
been considered to be involved in venous intimal thickening. We hypothesized
that venous wall injury after implantation in the arterial circulation is not only
induced by hemodynamic stress, but also by supra-physiological oxygen levels
leading to oxidative stress. Accumulating evidence indicates that oxidative
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stress is an important modulator of vascular cell functions and that it plays a
major role in several cardiovascular diseases. In venous bypass grafts, two
mechanisms might hamper the functionality of the conduit. First, when
excessive ROS overpower the endogenous antioxidant systems, impaired
endothelial cell function leads to decreased nitric oxide (NO) bioavailability.
Consequently, endothelium-mediated vasodilatation is impaired which
contributes to the risk of thrombosis related early graft failure. Secondly, it has
been shown that ROS induce several processes related to vascular remodeling
and inflammation, like NF-kB activation, MMP expression, and SMC
proliferation/migration19. Furthermore, research from the field of pulmonary
physiology has already demonstrated that human umbilical vein endothelial
cells (HUVEC) induce pro-inflammatory responses when exposed to
hyperoxia20. Finally, it has been demonstrated that elevations in ROS are
related to neointimal hyperplasia after vascular injury in experimental animal
models21. The origin of ROS in vein grafts and the relation with neointimal
hyperplasia development was not yet investigated. We found that supra-
physiological oxygen levels induced pro-inflammatory cytokine secretion in
VSMCs, which initiated quiescent venous SMC proliferation in vitro. We further
found that N-acetyl-L-cysteine (NAC) reduced cytokine levels in conditioned
medium from the hyperoxic VSMC culture. In agreement, the conditioned
medium no longer showed mitogenic potential in SMC culture. This finding was
supported by our experimental vein graft studies. First we found a significant
reduction in proliferating VSMCs in vein graft 1 week after implantation in the
NAC treated group in comparison to the control group. Second, at 3 weeks post
surgery it was shown that NAC treatment significantly reduced neointima
formation and stenosis in experimental vein grafts. We were not the first group
to show that NAC exerts vasculoprotective qualities and attenuates neointima
formation. However, these investigations were all performed in arterial models.
Moreover, we were the first to implicate supra-physiological oxygen levels in
the pathogenesis of vein graft disease. Although we do not neglect the
importance of hemodynamic stress in the development of venous neointima
formation, our findings might certainly add to the knowledge of vein graft
disease and offer new implementations for the prevention of venous neointima
formation.
Prevention of venous  neointimal hyperplasia 
With the presentation of aforementioned results we underscored the
inflammatory nature of venous neointimal hyperplasia, and supplemented the
current hypothesis of neointimal formation with novel culprit mediators.
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Moreover, we introduced possible intervention methods to inhibit the adverse
effects of these mediators. For many years efforts have been made to prevent
early and late venous graft failure. First, vascular interventionists stressed the
importance of risk factor reduction by introducing anti-thrombotic agents to
target early graft failure, and lipid lowering drugs to prevent late graft failure.
Second, the problem of venous neointimal hyperplasia was targeted by
introducing alternative conduits, like the internal mammary artery and synthetic
grafts. However, unidentified mediators continued to hamper the patency of
bypass grafts. Following the inflammation hypothesis of atherosclerosis, venous
neointimal hyperplasia was also thought to be mediated by inflammatory
processes. The role of pro-inflammatory and mitogenic cytokines has been
investigated extensively and several intervention methods have been designed
to target these growth factors. Both in vitro and in vivo, antibodies against
inflammatory cytokines proved efficient to inhibit SMC proliferation and
neointimal thickening22,23. Furthermore, gene therapy targeting distinct growth
factors still is a promising technique with adequate results in experimental
models24,25,26. However, up till now none of these intervention techniques
proved to be feasible in the clinical setting. First and foremost, the multifactorial
nature of neointimal hyperplasia is a plausible reason for the incomplete
inhibition of neointimal thickening, because several growth factor related
mechanisms occur simultaneously and cumulative. Thus, blocking or
elimination of distinct cytokines and growth factors will probably not
adequately reduce neointimal formation, and therefore request simultaneous
targeting of multiple growth factors at the same time. However, it seems
laborious to target all possible mediators of neointima thickening by antibody
treatment. The transcription factor nuclear factor-kappaB (NF-kB) plays a pivotal
role in the coordinated transactivation of cytokine and adhesion molecule
genes involved in neointimal formation. Therefore, direct inhibition of NF-kB
activation would be a promising alternative for generalized cytokine inhibition
in order to prevent inflammation related neointimal formation. In fact,
encouraging results were recently published showing that injury induced
intimal hyperplasia was inhibited using a ‘decoy’ cis element that blocked NF-kB
gene activation27. Subsequent inflammatory responses as adhesion molecule
expression and inflammatory cell influx were also significantly inhibited. As
mentioned before, in chapter 4 we showed that NAC significantly reduced pro-
inflammatory cytokine levels in SMCs and reduced neointimal thickening in
experimental vein grafts. NAC is known to be a potent inhibitor of NF-kB
activation28, thus might inhibit intimal hyperplasia through a NF-kB mediated
pathway. Although interesting, since NF-KB gene activation is the basis for
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numerous downstream cell processes, blocking NF-kB gene activation might
also lead to inhibition of protective (e.g. anti-inflammatory) processes that
counteract inflammation induced neointimal thickening. Furthermore, several
pro-inflammatory cytokines have been shown to exert contradictory effects on
SMCs (mitogenic versus inhibitory)29,30, and bifunctional responses during the
development of neointima formation31. However, it seems that the favorable
effect of NF-kB inhibition overrule the adverse effects.   
Inflammatory processes play a significant role in venous neointimal
formation and one of the most prominent and detrimental consequences is the
increase in SMC number within the inner layers of the vessel wall, mainly
caused by proliferation of locally residing SMCs. The final common pathway of
SMC proliferation composes the progression through the different phases of the
cell cycle, which comprises the Gap (G)1, DNA synthesis (S), G2, and mitosis
(M) phase. The cell cycle of the SMC could suffice as an attractive target for
intervention if it would be accessible for pharmacological agents. Cell cycle
progression, leading to cell proliferation is tightly regulated by the sequential
formation, activation and inactivation of a group of nuclear proteins32. Briefly,
complexes between cyclins and cyclin dependent kinases (CDK) that stimulate
cell cycle progression continually compete with cyclin dependent kinase
inhibitors (CKI) that impede cell cycling, which in turn is dependent on the
balance between pro- and anti-mitogenic signaling. During SMC quiescence,
the key CKIs p21, p27, and p57 inactivate cyclin-CDK complexes thus
preventing G1-S transition. After mitogenic signaling, proteolysis of CKIs result
in phosphorylation of retinoblastoma protein that subsequently evades its
inhibitory control over the transcription factor E2F leading to cell cycle
progression. To find out if the cell cycle machinery might be a functional target
for intervention, we examined if cells in venous neointimal lesions express
distinct patterns of cell cycle proteins. In chapter 5 we immunohistochemically
studied venous intimal hyperplasic lesions from arteriovenous fistulas (AVF) and
found typical expression of cell cycle promoters and inhibitors. We compared
the expression of cell cycle regulators cdk2, p21, p27, and proliferating cell
nuclear antigen (pcna) between healthy control veins and stenosed AVF lesions
and showed that venous neointimal lesions of AVFs express low p21 levels
versus high cdk2 and pcna levels. p27 levels did not differ significantly, which
is in agreement with previous reports suggesting that p27 is up-regulated at the
later phases of vascular response to injury33,34. Since the vascular specimens
used in our study were removed at the time of failure, we suggest that the acute
moment in the response to injury was captured and p27 upregulation was still
awaited. Also, it implies that boosting the levels of p27 in the venous wall might
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block unfavorable neointima formation. However, the first studies focused on
the genetic manipulation of p21 to reduce neointima lesions size35,36. Besides
genetic manipulation by means of adenoviruses, pharmacological agents have
been shown to influence cell proliferation by manipulating cell cycle regulating
proteins. Tranilast, an anti-allergic drug, was originally suggested to suppress
intimal hyperplasia after angioplasty37, which was elaborated later by Takahashi
et al who found Tranilast induced inhibition of SMC proliferation via up-
regulation of p2138. However, in a multicenter, randomized clinical trial,
administration of Tranilast did not improve either angiographic or clinical
restenosis compared with administration of placebo alone39. Around the same
time, the immunosuppressive agent Rapamycin was introduced because of its
suggested anti-proliferative potential, which is mediated by the effect on the
cell cycle regulator p27 by Rapamycin. In contrast to Tranilast, Rapamycin not
only proved to inhibit intimal hyperplasia after coronary angioplasty in a pig
model40, but in recent years consistently showed beneficial in prevention of
restenosis after stent placement in randomized controlled trials41-43. Moreover,
local application of Rapamycin substantially inhibited neointimal hyperplasia
of vein grafts in a mouse model, suggesting that Rapamycin may have
therapeutic potential for the treatment of vein graft disease44. Recently, Murphy
et al published optimistic results showing reduced neointima after pre-
treatment of saphenous veins with Rapamycin45. Clinical studies should now
point out if similar outcomes can be achieved in humans.
In chapter 6 we examined the potency of another immunosuppressive
agent, FK778 to inhibit SMC proliferation and neointima formation in vein
grafts. Former research already suggested a favorable result of orally
administered FK778 on neointima formation in a double-injury rat model of
restenosis. The foundation for this promising outcome was previously created
by Czech et al who proved that the family of malononitrilamides to which
FK778 belongs, exerts an anti-proliferative effect on vascular SMCs46. We found
that FK778 inhibited venous SMC proliferation in a dose dependent fashion in
vitro. In addition, neointima hyperplasia was significantly reduced by oral
administration of FK778 in a rat experimental vein graft model. All together, it
seems that FK778 treatment is a promising drug to enhance patency in venous
bypass grafts. However, up till now it remains obscure which molecular
mechanisms underlie the potency of FK778. Both inhibition of receptor tyrosine
kinase (RTK) activity and blocking of the pyrimidine synthesis pathway have
been suggested to reduce cell cycle progression47,48. Up till now however, it is
mainly believed that suppression of the novo pyrimidine biosynthesis is the key
mechanisms in SMC proliferation. This is supported by our study in which we
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found that addition of uridine, a nucleoside that can be utilized via the salvage
pathway to maintain the intracellular pool of pyrimidine nucleotides abolished
the effects of FK778.
As mentioned above Ross suggested that the immune system mediates the
inflammatory response within the vessel wall49. T-cell activation might
considerably enhance the initiating stages in neointima formation. FK778 has
been shown to block cellular (ie, T-cell) and humoral immune responses, and
by this an alternative method of action to prevent intima hyperplasia might be
proposed. 
We conclude that cell cycle interference either by genetic manipulation or
pharmacological intervention is a promising method to attenuate unfavorable
intima hyperplasia and warrants further clinical investigation.      
Suggestions for clinical trials
In addition to established treatments proven to be beneficial in most patients
receiving venous bypass grafts, several (pharmacological) intervention methods
could be considered. Beside the stipulation that potential drugs should be
feasible as well as effective to prevent bypass failure, evaluation of adverse side
effects is necessary before these drugs can be introduced in clinical practice.
NAC has proven to be efficient in our and other experimental animal model to
reduce neointimal formation possibly by inhibiting NF-kB activity as well as
scavenging free oxygen radicals. Since NAC has been used in several clinical
trials and no adverse effects were seen up to doses of 6000 mg it seems
acceptable to conclude that NAC can be administered safely. 
FK778 is still under development, but a recently completed clinical trial
did not show significant adverse effects50, thus it seems unlikely that the
positive effects on patency rates of vein grafts noticed in our study will be
hampered by side effects. 
Our finding that pre-existence of inflammatory cells in saphenous veins
destined to be implanted as vein grafts might predict vein graft occlusion might
help to discriminate between patients needing additional therapy and patients
for whom conservative treatment would suffice. 
Conclusions
The pathogenesis of neointimal hyperplasia in vein grafts is of multifactorial
origin; therefore a wide range of potential interventions is conceivable.
However, the predominant morphological feature of IH is smooth muscle
proliferation putting exacerbated cell cycle progression in the center of its
development and in the scope of promising interventions. 
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Chapter 1
In this thesis some novel mechanisms that might lead to intimal hyperplasia and
subsequent venous graft failure are highlighted and potential intervention
possibilities are suggested. Chapter 1 presents a comprehensive overview of the
pathogenesis of intimal hyperplasia with special emphasis on the role of SMC
proliferation herein. Also, attention is given to currently employed intervention
methods, in particular by pharmaceutical interference. In chapter 2 the
inflammatory nature of venous intimal hyperplasia is underscored by the
observation that macrophages and T lymphocytes co-localize with in intimal
hyperplastic lesions of failed bypass grafts as correlates to earlier reports in the
literature. Of more importance however is the finding that both macrophages
and T lymphocytes are detectable at higher levels in veins found to fail in the
year following bypass surgery, than in veins surviving this one year follow-up
period. Obviously, this implicates that immunohistochemical evaluation of
veins at the time of implantation as bypass grafts could be a prognostic tool and
might help to individualize medical treatment. Chapter 3 puts forward a novel
mechanism by which HSP60, a protein recently discovered to play a role in
vascular disease might induce venous intimal hyperplasia. Originally
considered responsible for intracellular protective processes, and lately
implicated in the auto-immune response hypothesis of cardiovascular disease,
e.g. atherosclerosis, we reported the direct mitogenic aspect of autologous
HSP60.  Furthermore, we emphasized the earlier suggested affiliation between
HSP60 and TLRs since we presented TLR2 and TLR4 as receptors by which
HSP60 mediates its mitogenic effects. First, we hereby suggest a novel
autocrine mechanism in the development of intimal hyperplasia and second we
propose a possible target for intervention. In chapter 4 we questioned whether
hyperoxia is a significant factor in the pathogenesis of venous bypass intimal
hyperplasia. Since arterial oxygen levels might be stressful to venous cells, we
proposed that relative hyperoxia might be an additional factor in the
inflammatory cascade leading to intimal hyperplasia. We found hyperoxia to
induce the release of pro-inflammatory and mitogenic cytokines by venous
SMCs. Since free oxygen radicals seem to be intermediaries between hyperoxia
and the subsequent intracellular inflammatory process, we tried to scavenge
these culprit factors by antioxidant treatment. N-acetyl cysteine, a strong
scavenger of free radicals proved to counteract the detrimental effect of
hyperoxia in venous SMCs. Furthermore, we showed that N-acetyl cysteine is a
potent inhibitor of neointima formation in a venous graft bypass model in the
rat, which advocates future application of this pharmacological agent in clinical
trials. In chapter 5 we addressed the final common pathway of intimal
hyperplasia. We examined the expression of cell cycle proteins in normal veins
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and intimal hyperplastic lesions. The high proliferation rate of venous SMCs
within these lesions correlated well to the expression profile of cell cycle
proteins. Since blocking cell cycle progression has proven efficient to restrain
cell proliferation, we suggested pharmacological manipulation of cell cycle
protein expression to interfere with venous neointima formation. Chapter 6
elaborates on the prevention of neointima formation by investigating the anti-
proliferative qualities of FK778, a better tolerated derivate of the known
immune-suppressive drug Leflunomide. First, we showed that FK778 inhibits
venous SMC proliferation in vitro. We substantiated our in vitro results by
showing that oral FK778 inhibited neointima formation in a rat venous bypass
model. In conclusion, the data presented in this thesis underscore the
inflammatory nature of neointima formation. Also, the role of two as yet
underestimated mediators in the development of neointima formation,
autologous HSP60 and supra-physiological oxygen, has been analyzed in more
detail and related to the pro-inflammatory profile within the venous graft wall.
Furthermore, our data suggest that pharmaceutical treatment might be
applicable to abolish the negative effects of these mediators or to intervene with
their down-stream pathways. 
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Samenvatting
Aderverkalking in de slagaders van de benen is een veel voorkomende
cardiovasculaire aandoening die nog te vaak tot ernstige invaliditeit leidt.
Gelukkig kan de vaatchirurg in veel gevallen een ader gebruiken om het bloed
om te leiden tot in het onderbeen. Helaas gaat deze “veneuze graft” in circa de
helft van de gevallen na verloop van tijd dichtzitten door “intima hyperplasie.”
Veneuze intima hyperplasie (IH) is het verdikken van de vaatwand door
uitbundig vermenigvuldigen van gladde spiercellen waaruit de normale
vaatwand grotendeels is opgebouwd. Dit kan dermate ernstige vormen
aannemen dat een veneuze graft faalt. In het huidige proefschrift worden tot
dusver onbekende mechanismen beschreven welke zouden kunnen bijdragen
tot het ontstaan van intima hyperplasie in veneuze grafts. Verder worden
therapeutische mogelijkheden aangedragen ter voorkoming van dit proces. In
hoofdstuk 1 wordt een uitvoerig overzicht verstrekt aangaande het ontstaan van
intima hyperplasie, waarbij vooral wordt ingegaan op de rol van de gladde
spiercel. Tevens worden de vooral medicamenteuze interventie mogelijkheden
belicht welke momenteel vaak worden toegepast. In hoofdstuk 2 wordt het
inflammatoire karakter van intima hyperplasie benadrukt. Hierin wordt
beschreven dat macrofagen en T-lymfocyten aantoonbaar zijn in veneuze
intima hyperplasie laesies, maar ook in venen voordat deze geïmplanteerd
worden als veneuze bypass. Deze ontstekingcellen zijn echter in grotere
aantallen detecteerbaar in venen welke falen binnen een jaar na implantatie in
vergelijking met venen welke langer dan 1 jaar open blijven. Deze bevinding
impliceert dat het kwantificeren van ontstekingscellen in natieve venen het lot
van de veneuze bypass voorspelt en daarmee gerichte therapie mogelijk maakt.
Hoofdstuk 3 beschrijft hoe humaan heat shock proteïne (HSP) 60 een rol speelt
in het ontstaan van veneuze IH. Het is reeds gesuggereerd dat HSP60 via een
auto-immuun reactie bijdraagt tot het ontstaan van atherosclerose. In dit
hoofdstuk wordt beschreven dat humaan HSP60 een direct mitogeen effect
heeft op veneuze gladde spiercellen door interactie met toll like receptor (TLR)
2 en 4. Hiermee wordt een nieuw autocrien mechanisme in het ontstaan van IH
en een mogelijk interventie doel geponeerd. In hoofdstuk 4 wordt het gevolg
van hoge zuurstof concentratie op veneuze cellen onderzocht. Omdat een vene
geïmplanteerd in de arteriële circulatie naast hemodynamische stress ook aan
een verhoogde zuurstofspanning wordt blootgesteld, veronderstelden wij een
bijdrage van relatieve hyperoxie aan de pathogenese van veneuze IH. Wij
concluderen dat hyperoxie veneuze gladde spiercellen stimuleert tot het
uitscheiden van inflammatoire en pro-mitogene cytokinen. Dit proces kan
geïnhibeerd worden door farmacologische interventie middels N-acetylcysteine,
een antioxidant. Vervolgens blijkt N-acetylcysteine de ontwikkeling van
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veneuze IH in een proefdier model tegen te gaan. In hoofdstuk 5 wordt de
celcyclus als het hart van IH belicht. Een aantal celcyclus eiwitten spelen een
belangrijke rol in het aansturen van de celdeling. Na kwantificeren van deze
celcyclus eiwitten in gezonde venen en arteriën en IH laesies blijkt de expressie
hiervan sterk gerelateerd te zijn aan het aantal delende cellen in IH laesies. Dit
biedt perspectief voor farmacologische interventie om celcyclus progressie
tegen te gaan. Een andere farmacologische interventie mogelijkheid wordt in
hoofdstuk 6 belicht. Hier wordt het experimentele immuno-suppressivum
FK778 onderzocht op anti-proliferatieve eigenschappen. Met behulp van
celkweek technieken en een proefdiermodel wordt aangetoond dat FK788 leidt
tot vermindering van veneuze celdeling en IH. 
Concluderend wordt met de resultaten in dit proefschrift de rol van
inflammatie in het ontstaan van veneuze IH onderstreept. Tevens worden
nieuwe moleculaire mechanismen in het ontstaan van IH belicht en
farmacologische interventie mogelijkheden geopperd.
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Vanzelfsprekend hebben door de jaren heen veel personen bijgedragen aan het
totstandkomen van dit proefschrift en ik ben jullie hiervoor dan ook zeer
erkentelijk. Graag wil ik nadrukkelijk dank uit laten gaan naar die mensen
zonder wie dit proefschrift niet had kunnen bestaan.
Prof. Dr. Cathrien A. Bruggeman. Vanaf mijn allereerste schreden binnen de
wetenschappelijke wereld schiep u de voorwaarden die essentieel bleken 
om mijn promotietraject af te ronden. Bovenal is het uw ogenschijnlijk
filantropische betrokkenheid bij mijn promotieonderzoek hetgeen mij het
meeste bij blijft.
Prof. Dr. Peter J.E.H.M. Kitslaar. Nog altijd zie ik het als een groot geluk dat ik
bij u ben begonnen als student-assistent, weliswaar onder directe begeleiding
van uw twee AIO’s. De directe en indirecte gevolgen van deze initiële stap
reiken ver en hebben tot buitengewoon waardevolle ervaringen geleid. Hoe
dan ook heeft de aanzet tot wetenschappelijk onderzoek onder uw leiding
menig deur geopend waarvan ik tot op heden de vruchten pluk, met als hoogtepunt
dit proefschrift. 
Dr. Frank Stassen. Je bent het meest direct betrokken geweest bij het creëren
van dit proefschrift. Vele ideëen heb ik in de loop der jaren over je uitgestort,
hetgeen voor mij meestal het meest interessant was. Ik ben blij dat jij het
overzicht hebt gehouden en mijn enthousiasme hebt weten te kanaliseren,
zodat uiteindelijk voldoende projecten tot wasdom zijn gekomen. 
Prof. Dr. Arnold Hoeks. Na het totstandkomen van het eerst verschenen
hoofdstuk hebben wij niet direct samengewerkt, alhoewel dit de volbrenging
van mijn proefschrift waarschijnlijk niet heeft gefrustreerd. Ons sporadisch
sociale onderhoud blijft zeer interessant, maar ik ben er niet van overtuigd dat
mijn talenten toereikend zijn om jouw wetenschappelijke gedachten te allen
tijde te kunnen volgen. Desondanks mag het duidelijk zijn dat dit proefschrift
er zonder jouw inbreng zeker niet was geweest. De eerste promovendus die
zijn proefschrift in het stadspark schrijft moet ik nog zien.
Dr. Tryfon Vainas en Dr. Ruben Dammers. Tryfon, het was een bijzondere
ervaring om bij jou te beginnen als “jeugdig” onderzoeker. Je nam niet alleen
mijn wetenschappelijke vorming als buitengewoon serieuze taak op je, maar
vond dat je me ook nog wat “sociale activiteiten” moest bijbrengen. Dat ik het
geleerde in jouw directe nabijheid aan je wou bewijzen leverde wel wat
spanningen op, alhoewel van voorbijgaande aard. Gelukkig gaf Ruben je even
wat lucht door me onder zijn leiding mijn eerste wetenschappelijke publicatie
te laten volbrengen. Ruben, van valse bescheidenheid kan men jou niet
betichten. De manier waarop jij op natuurlijk ingetogen wijze jouw ambities
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vervult dwingt zondermeer respect af. Al met al koester ik de tijden in “onze”
kamer, met eureka exclamaties na weer een unieke gedachte, gegrom over
kortzichtige reviewers, getier op computers en dat alles onder het genot van
een ijzersterke margarita. Ik hoop van harte dat onze gezamenlijke liefde voor
vasculaire geneeskunde, research en een oude whiskey of frisse cocktail ons
nog vaak bij elkaar mag brengen. 
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Chapter 1 - Figure 1. 
Different stages of vein graft disease. A. Hemodynamic forces (shear stress, tangential strain) alter
the vascular endothelium, which triggers a cascade of events, like recruitment of leukocytes and
platelets. B. Aggregation of platelets on the surface of the vessel wall induces thrombus formation
which hampers vein graft survival. C. Cytokines and growth factors are released by inflammatory
cells, generating a mitogenic milieu. SMCs migrate, proliferate and synthesize extracellular matrix
components. D. Late atherosclerosis. Accumulation of macrophages, T-lymphocytes, and foam
cells in a fibrocalcific lesion. Inflammatory mediators and proteases induce thinning of the fibrous
cap, rendering the plaque weak and susceptible to rupture and thrombus formation. Modified
from Dzau et al, 2002.
Chapter 1 - Figure 2. 
Illustration showing the beneficial effects of nitric oxide (NO). NO exerts its protective effects by
inducing SMC relaxation; inhibiting SMC proliferation, migration, and extracellular matrix
synthesis; inhibiting platelet and leukocyte adhesion and activation; and protecting endothelial
integrity. Modified from Dzau et al, 2002.
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Chapter 2 - Figure 2. 
Immunohistochemical representation of macrophage and T-lymphocyte distribution in failed
bypass sections and saphenous vein segments. A-C: abundant expression of CD3 immunoreactivity
(T-lymphocyte) in failed bypass graft segment (A), while T-cell presence in DIH vein segment is
clearly less pronounced. CD3 expression in NDIH vein segment (C) is virtually absent. D-F:
macrophages (CD68 immunoreactivity) mainly localize in the media and adventitia of failed bypass
graft segment (D). To a lesser extent, macrophages also are present in the media and adventitia of
DIH vein segments (E). Macrophage count is almost nil in NDIH veins (F). 
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Chapter 3 - Figure 1. 
Immunohistochemical analysis of TLR2, TLR4 and HSP60 proteins. A, doublestaining for TLR4 (red)
and HSP60 (blue) in AVF neointimal lesion. Arrows indicate double-positive cells for TLR4 and
HSP60 (detail). B, doublestaining for TLR2 (red) and HSP60 (blue). Arrows indicate double-positive
cells for TLR2 and HSP60 (detail). C and D, Doublestaining for TLR2 or TLR4 (red) respectively and
HSP60 (blue) in control venous segments. Arrows indicate diffuse TLR2 and TLR4 staining in medial
cells. Hardly any positive HSP60 immunoreactivity could be detected. Bar=100μm.
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Chapter 4 - Figure 2. 
Medium from hyperoxic VSMCs induces proliferation of quiescent normoxic VSMCs, which is
prevented by NAC. Proliferation indices in normoxic VSMCs after 48-h incubation with conditioned
medium retrieved from VSMCs after 24-72 h of hyperoxia induced a significant increase in the
number of Ki-67 positive cells (red bars, * P < .01 versus incubation with control medium).
Administration of NAC to quiescent VSMCs reduced the proliferative effect of medium from
hyperoxic VSMCs (yellow bars, # P < .05 versus medium from hyperoxic VSMCs, ie versus red bars).
The proliferative response of quiescent VSMCs was completely abolished by conditioned medium
from hyperoxic NAC-treated VSMCs (blue bars, † P < .05 versus medium from hyperoxic VSMCs
that had not been treated with NAC, ie versus yellow bars). Data are expressed as mean ± SE of
four experiments.
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Chapter 4 - Figure 3. 
Systemic treatment with NAC reduces VSMC proliferation in rat venous grafts. VSMC proliferation
is significantly lower in vein grafts of NAC-treated (B; 150 mg/kg/d orally; n=7) compared with
control rats (A; n=6) at 7 days of surgery, as demonstrated by BrdU immunohistochemistry
(arrowheads). Scale bars represent 100 μm.
Chapter 5 - Figure 1. 
Immunocytochemical staining of healthy and intimal hyperplastic vascular segments. Shown are
Fast Red-stained nuclei in normal veins: (A) p21Waf1, (B) p27Kip1, (C) cdk2, and (D) PCNA; normal
arteries: (E) p21Waf1, (F) p27Kip1, (G) cdk2, and (H) PCNA; AVFs: (I) p21Waf1, (J) p27Kip1, (K) cdk2,
and (L) PCNA expression. Bar, 100 μm.
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Chapter 6 - Figure 3.
Three weeks after vein grafting. Representative images after Lawson staining of a control vein
graft (A) and FK778 treated vein graft (B). Arrowheads represent the lamina elastica interna. The
media-aventitia border is indicated by small arrows. The large arrow indicates the native vein in situ
adjacent to the grafted vein, which shows normal intimal and medial thickness. Notice the marked
increase in medial thickness of both control and FK778 treated vein grafts compared to the native
vein. Moreover, medial thickness is similar in both vein grafts. Scale bar: 100 μm.
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